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1. INTRODUCTION		
The remarkable achievements obtained in the fields of nanosciences and 
nanotechnologies have led to applications in many different fields of human 
activity. The miniaturization of devices to nanometric size increases their 
potentialities. The keystone in the unique material properties resides in their 
size, surface structure and interparticle interactions. [1] 
The application of nanotechnologies in medicine is called nonanomedicine, 
which is defined as “the process of diagnosing, treating or preventing of 
disease and traumatic injury, relieving pain and preserving and improving 
human health, using molecular tools and knowledge of the human body”. 
Nanomedicine focus on two main fields: 
1. development of diagnostic systems; 
2. new drug delivery systems. 
The materials commonly used to prepare nanoparticulate systems for 
pharmaceutical and therapeutic release include: organic nanoparticles 
(dendrimers or polymers), organic or inorganic ensembles (gold, silver and 
ferric oxide nanoparticles), liposomes or proteins and peptide-based 
nanoparticles. 
In recent years, in the field of nanotechnology, hydrogel nanoparticles have 
gained considerable attention, as one of the most promising nanoparticulate 
drug delivery systems. Hydrogel nanoparticulate materials would ideally 
have the features and characteristics of both hydrogels and nanoparticles. 
For these reasons it seems convenient to combine the characteristics of a 
hydrogel system (e.g. hydrophilicity and extremely high water content) with 
all the advantages of the nanoparticles, mainly long life span in the blood 
circulation and the possibility of being actively or passively targeted to the 
desired biophase (e.g., tumor sites). 
 
1.1 NANOPARTICLES		
Nanoparticles are solid colloidal particles with diameter in the range 1-1000 
nm. They are distinguished into nanospheres and nanocapsules. 
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Nanospheres have a monolithic structure with the drug dispersed inside the 
polymeric matrix or adsorbed onto their surface. Nanocapsules, instead, 
have a membrane-wall structure with the drug entrapped inside the core or 
adsorbed onto their external surface. The polymeric matrix can be natural or 
synthetic: generally natural polymers are preferred because of their 
biocompatibility, biodegradability and relative non-toxicity. Because of this 
chitosan is considered a polymer of prime interest. 
 
1.2	CHITOSAN		
Chitosan (Fig.1) is a cationic polysaccharide with excellent biological 
properties such as biocompatibility, biodegradability, mucoadhesivity and 
non-toxicity; moreover, it exhibits antimicrobical, antiviral and 
immunoadjuvant activities. Chitosan is essentially composed of D-
glucosamine with some residues of and N-acetil-D-glucosamine linked by β 
(1-4) bonds.  
 
 
 
Chitosan occurs rarely in nature and it is obtained by incomplete 
deacetylation of chitin (Fig.2), a homopolymer of β (1-4) linked N-acetil-D-
glucosamine present in the shell of crustaceans and mollusks, the cell walls 
of fungi and the cuticle of insects.  
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The microstructure of chitosan depends on whether the deacetylation 
reaction is carried out under homogeneous or heterogeneous conditions: 
chitosan obtained by a heterogeneous procedure is not soluble in water but it 
becomes soluble in acid conditions. Water-soluble chitosan is instead 
obtained with homogeneous reaction. The acetylation of highly deacetylated 
chitin can also produce soluble chitosan. As a result, chitosan is available, on 
the market, in different forms that differ in molecular weight (MW) and 
deacetylation degree. Moreover, chitosan can be modified thanks to the 
presence of -NH2 and –OH groups on the repetition units, leading to different 
derivatives. The glycoside bond of chitosan is a hemiacetal and hence it is 
unstable in acid conditions and can be hydrolyzed with a consequent 
decrease of MW and viscosity. 
Chitosan has been found to enhance drug penetration not only across cell 
monolayer, such as the intestinal [2,3] and nasal epithelia [4], but also 
stratified cell layers, such as the buccal [5,6], vaginal [5] and corneal 
epithelia [7,8]. 
In virtue of all the above properties, chitosan can easily be processed into 
diverse forms such as films, threads, membranes, tablets and micro- or nano-
particles. In particular, chitosan nanoparticles have become of great interest 
as polymeric platforms for the development of new pharmacological and 
therapeutic drug delivery systems. Chitosan nanoparticles have been found 
appropriate for non-invasive routes of drug administration: oral, nasal, 
pulmonary and ocular routes. These applications are facilitated by the 
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absorption-enhancing effect of chitosan. 
	
1.3 PREPARATION	OF	CHITOSAN	NANOPARTICLES		
The methods used to prepare nanoparticles consider natural nanoparticles 
tendency to agglomerate because of their high surface free energy. To 
prepare chitosan nanoparticles, different techniques have been used, but the 
choice of one particular method with respect to others has to consider the 
nature of drug to be entrapped, the delivery system, the administration route 
and the absorption site. The principal methods are: ionotropic gelation, 
coacervation, emulsion and micro-emulsion techniques and auto-assembling 
of hydrophobically modified chitosan.  
1.3.1	Ionotropic	gelation	
This method consists in ionic crosslinking of chitosan with multivalent 
counter-ions such as Fe(CN)6-4, Fe(CN)6-3, citrate and sodium 
tripolyphosphate (TPP). The procedure is very simple because it is carried 
out in aqueous medium and does not involve the use of organic solvents. 
The nanoparticles can be obtained by the addition of a dilute solution of 
chitosan to one solution of TPP, or vice versa, under stirring. Nanoparticle 
size depends on the concentration of both chitosan and TPP. This technique 
was reported in 1997 by Calvo et Al, [9] but the main problematic aspects 
are the time-stability of colloidal dispersion, which can require the addition 
of stabilizers, and the use of very diluted solutions, which may be 
inconvenient when large amounts of nanoparticles are required. 
1.3.2	Complex	coacervation	
Coacervation is obtained by mixing two polyelectrolytes with opposite 
charge. The polyelectrolyte complex produces an insoluble film or a barrier 
that covers the particles. Hu et Al. [10], prepared chitosan-poly (acrylic acid) 
(PAA) nanoparticles by dropwise addition of diluted chitosan solutions to 
PAA aqueous solutions or vice versa, under magnetic stirring. In either cases 
the formed nanoparticles had a core and an external shell, but the micro 
photos showed a solid structure when chitosan was added to the solution of 
PAA, instead, when they were prepared by adding PAA to the chitosan 
solution, nanoparticles were hollow. Also the zeta potential was influenced 
by the procedure: nanoparticles with a positive charge were obtained by 
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adding PAA to chitosan whereas nanoparticles with a negative charge were 
obtained in the opposite way. 
Similarly to ionotropic gelation, complex coacervation is a mild and useful 
method for obtaining nanoparticles, but it requires the use of very diluted 
solutions and pH control during preparation, in order to avoid nanoparticle 
agglomeration. 
1.3.3	Micro-emulsions	
To prepare micro-emulsions, the following procedure may be followed. An 
aqueous solution of chitosan containing the drug is dispersed in an oily 
phase, composed of an organic solvent and a surfactant, under stirring in 
order to avoid any turbidity. Then, a crosslinking agent is added and the 
organic solvent is evaporated. To remove the surfactant, the solid product is 
washed with a water/acetone 80:20 v/v or a salt is added. In the latter 
instance, the dispersion is dialyzed and lyophilized. With this procedure, 
nanoparticles of less than 200 nm are obtained, however major 
disadvantages are represented by the use of the organic solvent and the 
complexity of the washing step. 
1.3.4	Self-assembling	of	hydrophobically	modified	chitosan	
Nanoparticles based on modified chitosan were obtained by hydrophobic 
modification of a soluble derivative of chitosan. Nanoparticles based on 
hydrophobically modified glycol-chitosan (HGC) were prepared as 
paclitaxel carriers [11]. In a phosphate buffered saline pH 7.4, chitosan 
conjugates lead spontaneously to the formation of thermodynamically stable 
nanoparticles of less than 200 nm and. These nanoparticles have a 
hydrophobic core and a hydrophilic shell and, for this  
reason, can be used as carriers of either hydrophobic or hydrophilic drugs. 
 
1.4 MAIN	PHARMACEUTICAL	APPLICATIONS	OF	CHITOSAN		
The key considerations that justify the interest in chitosan is that this 
polymer is biocompatible and does not elicit adverse reaction when in 
contact with human cells. Ubiquitous enzymes in the human body can 
degrade chitosan and oligomers can activate macrophages and stimulate 
synthesis of hyaluronans. Moreover, tumor cells recognize chitosan and it 
can selectively bring drugs to the target. 
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1.4.1	Oral	route	
Oral route is the most widely used and most readily accepted form of drug 
administration. However, most orally-administered drugs face several 
problems such as poor stability in the gastric environment. For example, 
peptides and protein drugs, during transit trough the gastrointestinal tract, 
have to cross the mucus layer and epithelial absorption barriers. 
Chitosan is soluble at acid pH values and becomes insoluble at 
approximately pH 6.5. Nevertheless, an enteric coating can protect chitosan 
from the acidity of the stomach. When the preparation reaches the intestine, 
the enteric layer dissolves at the comparatively high pH and the drug–
bearing chitosan core remains exposed to bacterial enzymes and releases the 
drug. This is an advantage because chitosan in the solid form would not 
flocculate the bacteria while it would remain exposed to the hydrolytic 
action of the bacterial enzymes. Chitosan capsules enteric coated with a 
layer of hydroxypropylmethyl cellulose phthalate have been evaluated for 
colon delivery of drugs [12].  Studies carried out in wistar rats using insulin 
as drug showed improvement in absorption of insulin promoted by these 
capsules. Peak of insulin plasma concentration and hypoglycemic effect 
were seen 6-12 h after the oral administration of chitosan capsules loaded 
with insulin. 
1.4.2	Parenteral	route	
Chitosan and chitin were parenterally administered to mice and their toxicity 
was evaluated in comparison to oral administration [13].  It was found that 
mice treated with intraperitoneal injections of 5 mg of chitin every two 
weeks were normal over a period of 12 weeks. 
Injection of in situ gel-forming biopolymers is becoming increasingly 
attractive for the development of therapeutic implants and vehicles. 
Subcutaneous injection of a chitosan gel with morphine sulfate was found to 
be stable during-long term storage [14]. Beagle dogs that received 
subcutaneous injections of this gel presented constant plasma concentration 
compared with conventional morphine sulfate. The antinociceptive actions 
of morphine were also sustained with these injectable gels compared to the 
free drug in the experimental rats [15].  
1.4.3	Transdermal	route	
Transdermal drug delivery systems (TDDS) offer many advantages in 
comparison to the conventional dosage forms because they avoid first-pass 
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metabolism, increasing patient compliance and reducing toxicity. Effective 
transdermal drug delivery involves permeation of the drug through a number 
of barriers: the delivery system itself, the epidermis, the dermis and in the 
case of systemic drugs, endothelial cell walls. The stratum corneum is the 
primary barrier to drug delivery, in effect, skin that had the stratum corneum 
removed was highly permeable. The barrier function of stratum corneum is 
due to the presence of extracellular lipids within the paracellular space.  
A chitosan-based transdermal delivery system was developed using cross-
linked chitosan membrane and chitosan gel [16] where the membrane was 
the rate controlling device and the gel acting as the reservoir: the cross-link 
density of the membrane dictated the drug permeability. It has been 
suggested that water-soluble drugs permeate mainly through the pores in 
chitosan membrane, whereas hydrophobic drugs permeate by both partition 
and pore mechanisms. 
1.4.4	Ocular	route	
Traditional aqueous solutions, suspensions and ointments for ophthalmic use 
have the disadvantage that the major part of the drug is lost because of the 
nasolacrimal drainage; therefore, repeated administrations are needed. The 
prime requirement for the controlled delivery of ophthalmic preparations is 
bioadhesiveness that increase the contact time with the cornea, leading to 
improved drug absorption at the site.  
Chitosan solutions have viscoplastic and pseudoplastic characteristics that 
do not modify the lacrimal film, thus providing a good patient compliance. 
Moreover, chitosan and its derivatives open the tight junction between 
epithelial cells, either by intracellular route, or through a mechanism based 
on the positive charges of the polymer, which interact with the cell 
membrane, resulting in a structural reorganization of tight junctions-
associated proteins [17,18]. Chitosan can develop hydrogen bond or ionic 
interaction between its positively charged amino groups and the negatively 
charged sialic acid residues of mucins, depending on environmental pH [17].  
Felt et Al. [19] reported that co-administration of ofloxacin and chitosan in 
eyedrops increased the bioavailability of the antibiotics. The authors 
ascribed this effect to the high viscosity of chitosan solution. Another study 
showed the ability of chitosan-HCl and N-trimethyl chitosan, added to 
ofloxacin eyedrops, to improve transcorneal antibiotic transport [20]. 
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1.5 PHARMACEUTICAL	APPLICATIONS	OF	CHITOSAN	
NANOPARTICLES		
Considerable research efforts have been directed towards developing safe 
and efficient chitosan-based particulate drug delivery systems because of 
their biodegradability, biocompatibility, low toxicity, and simple and mild 
preparation methods. 
1.5.1	Oral	administration	
The use of polymeric nanoparticles for encapsulating peptides and protein 
drugs is a promising approach for protecting the biological molecules from 
enzymatic degradation. In addition, it has been reported that particles 
smaller than 500 nm can cross the intestinal mucus layer by the epithelial 
cells by endocytosis [21].  
Chitosan nanoparticles have the advantage to be muchoadhesive, which 
increases residence time in the intestine improving drug bioavailability [22].  
Oral nanoparticles can protect drugs from degradation in the gastrointestinal 
tract and improve drug absorption. Yin et Al [23] developed a promising 
vehicle for oral delivery. Trimethyl chitosan-cysteine conjugate (TMC-Cys) 
was synthesized in an attempt to combine the permeation-enhancing effects 
of TMC and the mucoadhesion of thiolated polymers related to different 
mechanisms. The TMC-Cys nanoparticles, obtained by self-assembly, 
possessed spherical morphology, uniform size, positive zeta potential and 
high insulin encapsulation efficiency. Mucoadhesion and permeation 
enhancing effect of TMC-Cys nanoparticles were significantly higher than 
those of TMC nanoparticles. 
Insulin-loaded, pH-sensitive chitosan nanoparticles were formulated by 
ionic-crosslinking with hydroxypropyl methylcellulose phthalate (HPMCP) 
as a pH-sensitive polymer [24].  In vitro results revealed a superior acid 
stability of CS-HPMCP nanoparticles with a significant control over insulin 
release and degradation in simulated acid conditions with or without pepsin. 
1.5.2	Nasal	and	pulmonary	administration	
Pulmonary and nasal routes are the other mucosal pathways that are 
attracting considerable attention as alternative routes for peptide and protein 
delivery because they involve very large surface areas and less intracellular 
and extracellular enzymatic degradation. Fernàndez-Urrusuno et al. [25] 
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found that chitosan nanoparticles were efficient vehicles for the transport of 
insulin through the nasal mucosa. The satisfactory in vivo results obtained by 
these authors confirmed the potential of these drug delivery systems as drug 
carriers through distinct mucosal route. 
1.5.3	Ocular	administration	
The main problems of conventional ocular therapy are short residence time, 
drug drainage and frequent instillation. Nanoparticles seem to be promising 
vehicles for designing new controlled delivery systems to improve the 
bioavailability of drugs for ophthalmic diseases. In fact, chitosan 
nanoparticles have been used to improve ocular drug transport and to 
enhance the corneal penetration. De Campos et al. have shown that chitosan 
nanoparticles remained attached to the rabbits’ cornea and conjunctiva for at 
least 24 hours [26]. 
Recently, nanoparticles consisting of hyaluronic acid and chitosan, which 
exhibit very low toxicity and have the ability to enter the corneal epithelial 
cells by CD44 receptor-mediated endocytic uptake, have been described 
[27]. 
1.5.4	Parenteral	administration	
The biodistribution of nanoparticles depends on their size, surface charge 
and hydrophobicity [28]. The particles with diameter greater than 100 nm 
are rapidly absorbed by the reticuloendothelial system (RES), while smaller 
ones tend to have a prolonged circulation time. 
Following intravenous injection, chitosan nanoparticles exhibited a marked 
tendency to accumulate in a number of tumors [29, 30]. One of the possible 
reasons for this phenomenon may be the poor tumor vasculature. Nano-sized 
particles can be administered intravenously because the diameter of the 
smallest blood capillary is approximately 4 µm. 
1.5.5	Cancer	therapy	
Chitosan itself has a certain antitumor activity and its positive charge can 
neutralize the negative charge on the tumor cell surface, resulting in 
selective absorption. Thus, chitosan nanoparticles can increase drug 
concentration in the tumor site and improve therapeutic effects [31]. 
Janes et al. [32] evaluated the potential of chitosan nanoparticles as carriers 
for doxorubicin. The challenge was to entrap a cationic, hydrophilic drug 
into nanoparticles formed by ionic gelation of the positively charged 
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chitosan. To achieve this objective, the authors formed a complex between 
doxorubicin and dextran sulfate and no dissociation of the complex was 
observed upon the formation of nanoparticles. Evaluation of the activity of 
doxorubicin-loaded nanoparticles in cell cultures indicated that they were 
able to maintain cytostatic activity relative to free doxorubicin. Confocal 
studies showed that doxorubicin was not released in the cell culture medium, 
but entered cells while being associated to nanoparticles. 
1.5.6	Carrier	of	other	drugs	
Chitosan nanoparticles can also load other drugs including antivirus, 
antiallergic and hormonal drugs.  
For example, Li and Luan [33] prepared tranilast-loaded chitosan 
nanoparticles for allergic diseases with a particle size of 285.5 nm and 
encapsulation efficiency of circa 82%. 
 
1.6 CHEMICALLY	MODIFIED	CHITOSAN		
Various chemical modifications of chitosan have been studied in order to 
improve its solubility and applications. Chitosan in its protonated form 
facilitates the paracellular transport of hydrophilic drugs by combination of 
bioadhesion and a transient widening of the tight junction in the membrane. 
However, it is incapable of enhancing the absorption in the small intestine’s 
more basic environment. Kotzè et al. hypothesized that polymers such as 
unmodified chitosan with a primary amino group may not be optimal ones in 
opening tight junctions, but the polymers or derivatives with different 
substituents, basicities or charged densities will have the same or even 
increased efficiency [34]. In particular there was the necessity of chitosan 
derivatives with increased solubility, especially at neutral and basic pH 
values [35,36].  Attempts to introduce positive charge on the polymer chain 
appear to be rational. 
N-Trimethyl chitosan chloride  (TMC) is a chitosan derivative obtained by 
quaternizing the primary amino group of chitosan with methyl iodide. TMC 
has been proved to effectively increase the permeation of hydrophilic 
macromolecules across the mucosal epithelia. Zambito et al. [37] 
investigated the effects of TMC on the transcorneal transport of 
dexamethasone and tobramycin and they founded that TMC enhanced 
transcorneal transport via the transcellular route, whereas it was unable to 
	 11	
open the tight junction between corneal cells.  
N,O-[N,N-diethylaminomethyl(diethyldimethyleneammonium)n methyl] 
chitosans (Fig.3) are prepared by reacting chitosan with 2-diethylaminoethyl 
chloride  (DEAE-Cl) under different conditions. The ability of such 
derivatives to promote the penetration of hydrophobic (rhodamine 123), as 
well as hydrophilic (fluorescein sodium) drug models, across the excised 
porcine buccal mucosa was demonstrated [38]. 
 
 
 
 
 
 
 
 
 
Thiolated chitosan 
N,O-[N,N-diethylaminomethyl(diethyldimethyleneammonium)nmethyl] 
chitosans have a high fraction of free, unsubstituted, primary amino groups 
available for covalent attachment of thiol-bearing compounds, via formation 
of 3-marcaptopropionamide moieties. This has led to water-soluble thiolated 
chitosan-quaternary ammonium conjugates (Fig.4.) These conjugates have a 
permeability-enhancing potential, tested using the Caco-2 cell monolayer 
and the excised rat jejunum as substrates [39]. On the basis of the obtained 
results, the quaternary ammonium groups of these derivatives were ascribed 
to reversibly open the epithelial tight junctions and also perturb the plasma 
membrane of the epithelial cells. Thiol groups are believed to keep the 
polymer adherent to epithelium by reacting with the thiols of the epithelium 
mucus to form disulphide bonds, thus favoring the permeability-enhancing 
action of the positive ions. Zambito and Di Colo [40] also investigated the 
synergism of quaternary ammonium and thiol groups. The thiomer resulted 
more effective than the parent non-thiolated derivatives in promoting the 
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transcorneal absorption of dexamethasone and showed promise of enhancing 
the intraocular bioavailability. The quaternary ammonium ions of the 
thiomer are responsible for both the permeabilization of corneal epithelium 
and the polymer mucoadhesion, while the thiols increase the latter. This 
synergic action is at the basis of the polymer bioactivity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.7 NANOPARTICLES	BASED	ON	CHITOSAN	DERIVATIVES		
The derivatization of chitosan changed the physicochemical, 
biopharmaceutical and biological properties of parent chitosan and each 
derivative type lent itself to preparing nanoparticles with their own physical 
properties (size, shape, surface change), drug encapsulation, release 
capability, biopharmaceutical and biological properties (mucoahesivity, 
ability to promote drug transport across biological barriers, aptitude for 
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internalization within cells, toxicity). 
1.6.1	Nanoparticles	based	on	quaternized	derivatives	
The major drawback of unmodified chitosan as an absorption promoter is its 
insolubility at physiological neutral pH. Therefore, the primary amino 
groups of its repeating units have been quaternized to bestow fixed, pH-
independent positive charges on the polymer, thus making it soluble and 
active as an absorption promoter at physiological pH. 
The interaction of quaternized chitosans with polyanions resulted in particles 
in the nanosize range. Proteins or macromolecular drugs have been 
encapsulated in these nanoparticles.  
Ovalbumin was encapsulated in nanoparticles obtained by ionotropic 
gelation of TMC with TPP and studied as a nasal delivery system for 
proteins [41]. No cytotoxicity of nanoparticles on Calu-3 cells, a model of 
human respiratory function, was observed, whereas a partially reversible 
cilio-inhibiting effect on the ciliary beat frequency of chiken trachea was 
observed. Other authors studied similar TMC/TPP nanoparticles, loaded 
with fluorescein isothiocyanate dextran, as a model of macromolecular drugs 
[42]. In analogy with the free TMC, the TMC/TPP nanoparticles exhibited 
the property of opening the tight junctions between cells in the Caco-2 
monolayer in vitro and the rat intestinal epithelium ex vivo, thus promoting 
the permeation of fluorescein isothiocyanate dextran across the two 
epithelium models. 
Nanoparticulate systems loaded with insulin were prepared with N-triethyl 
chitosan (TEC) and N-dimethylethyl chitosan by gelation from 
polyelectrolyte complex formation (PEC) [43]. Insulin was transported ex 
vivo across the colon membrane of rats when it was formulated into 
nanoparticles based on quaternized derivatives, better than into 
tnanoparticles based on plain chitosan. Compared to free insulin, in vivo 
colon absorption was enhanced by using insulin-loaded nanoparticles. 
1.6.2	Nanoparticles	based	on	thiolated	derivatives	
The thiol groups immobilized on these polymers are supposed to give 
exchange reaction with disulfide bonds within the mucus or oxidation 
reactions with cysteine-rich subdomains of mucus glycoproteins, both 
resulting in the formation of disulfide bonds between thiolated chitosan 
derivatives and the mucus, which improve the polymer mucoadhesivity. 
Nanoparticles prepared from this type of chitosan derivatives were supposed 
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to be themselves mucoadhesive and hence, apt to make nanocarriers for oral 
drug delivery. In fact, enhanced mucoadhesive properties of nanoparticles 
prepared by gelation of chitosan-N-acetyl cysteine conjugate (chitosan-
NAC) with TPP, compared with unmodified chitosan nanoparticles, were 
found by Wang et al. [44]. Enhanced insulin in vivo absorption via nasal 
mucosa was found by these authors when insulin-loaded chitosan-NAC/TPP 
nanoparticles were administers intranasally to rats. Another thiolated 
chitosan derivative, chitosan-4-thiobutylamidine (chitosan-TBA) was used 
by Bernkop-Schnürch et al. [45] to develop a mucoadhesive nanoparticulate 
delivery system. The polymer was first cross-linked ionotropically by TPP, 
followed by stabilization of the resulting nanoparticles via formation of 
inter- and intra-chain disulfide bonds by thiol oxidation with H2O2. 
Subsequently, TPP was removed by dyalisis. The covalently cross-linked 
particles would not disintegrate in the acid medium of the stomach. The 
adhesion to porcine intestinal mucosa was studied after incorporation of 
fluorescein diacetate into nanoparticles. The more thiol groups were 
oxidized, the lower was the nanoparticles mucoadhesivity, nevertheless, 
even when as much as 90% of all thiols were oxidized, the mucoadhesivity 
of chitosan-TBA nanoparticles was twice as high as that of unmodified 
chitosan particles. 
 
1.8 HYDROGELS		
Hydrogels are composed of a three-dimensional polymer network that has a 
high number of hydrophilic groups. The hydrogel can absorb large quantities 
of water without disintegrating or dissolving. The high water content of  a 
hydrogel renders it compatible with most living tissue and the viscoelastic 
nature of hydrogel minimizes damage to surrounding tissue when it is 
implanted in the host. These characteristics make hydrogel an ideal 
candidate in biomedical applications. In addition, hydrogels can serve as a 
supporting material for cells during tissue regeneration as well as drug 
delivery systems because the hydrogel’s physicochemical properties are 
similar to the native extracellular matrix both compositionally and 
mechanically [94]. The hydrogel will become responsive to environmental 
stimulation if the polymer network is endowed with functional groups [95]. 
The stimulation may derive from environmental changes, such as in pH, 
biomolecules, electric or magnetic field, light ray etc. Due to the stimulation, 
the hydrogel undergoes a volume or phase transition due to molecular 
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interactions resulting in changes in the network such as swelling, collapse or 
sol/gel transition. 
In a general view, hydrogels can be classified on the basis of a variety of 
characteristics, including the nature of side groups (neutral or ionic), 
mechanical and structural features (homo- or co-polymer), physical structure 
(amorphous, semicrystalline, hydrogen bonded, supramolecular and 
hydrocolloidal) and responsiveness to physiological environmental stimuli 
(pH, ionic strength, temperature, electromagnetic radiation, etc.). The 
polymers commonly used in preparation of hydrogels with pharmaceutical 
and biological properties are from natural or synthetic origins. Hydrogels of 
natural origin may show mechanically optimal characteristics and may exert 
immunogenicity or evoke inflammatory responses due to the presence of 
immunogen/pathogen moieties. They also offer various advantageous 
properties such as being non-toxic and biocompatibility, and show 
remarkable physicochemical properties that make them suitable for different 
applications in drug delivery systems [96]. 
1.8.1 Chitosan/β-glycerophospate	hydrogels	
Chitosan dissolves in acid environments via protonation of its amino groups. 
Once dissolved, chitosan remains in solution up to pH value in the vicinity 
of 6.2. Neutralization of chitosan aqueous solution to pH values exceeding 
6.2 leads to the formation of a hydrate gel-like precipitate. Effort on chitosan 
neutral solution was first proposed by Chenite et al. [97]. They found that 
chitosan solutions remain liquid below room temperature, even with a pH 
values within a physiologically acceptable neutral range from 6.8 to 7.2, in 
the presence of β-glycerophosphate salt (β-GP). The system becomes 
thermally sensitive, that is, it is liquid at room temperature and solidifies as 
temperature increases to body temperature (Fig.5) [98]. 
 
Fig.5:	The	chitosan/β-GP	formulation	at	room	temperature	(left)	and	at	37°C	(right)	[98]	
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β-GP plays three essential roles in this system: 
1) increasing the pH into the physiological range of 7.0-7.4; 
2) preventing immediate gelation or precipitation; 
3) allowing controlled gel formation when a temperature increase is 
imposed. 
The sol-to-gel transition temperature is pH-sensitive and gelling time is 
shown to be temperature dependent. The interactions responsible for the 
sol/gel transition include: 
1) the increase of chitosan interchain hydrogen bonding as a consequence of 
the reduction of electrostatic repulsion due to the basic action of the salt; 
2) the chitosan-β-GP electrostatic attractions via the ammonium and the 
phosphate groups; 
3) the chitosan-chitosan hydrophobic interactions that should be enhanced 
by the structuring action of glycerol on water. 
The solution behavior of chitosan/β-GP hydrogel is affected by the 
concentration of chitosan and β-GP. The pH of chitosan solution increases 
with increasing β-GP concentration due to the neutralizing effect of the 
phosphate groups. The pH increase with polymer concentration is due to 
consumption of H+ by the protonation of the free amino groups. 
1.7.1.1	Application	of	chitosan/β-GP	hydrogels	
The most common mechanism of drug release from hydrogels is passive 
diffusion and it is primarily dependent on the mesh sizes within the matrix of 
the gel. The biochemical properties and the three-dimensional networks of 
chitosan hydrogels offer wide applications in biomedical fields including 
local drug delivery and tissue engineering. 
Local drug delivery 
Due to the advantage of pH sensivity and mucoadhesive properties, 
chitosan/β-GP based hydrogels are effectively used for delivery of 
proteins/peptides, growth factors, anti-inflammatory drugs, antibiotics, as 
well as in gene therapy. 
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Peng, Sun et al. [99] prepared nanoparticles containing insulin phospholipid 
complex loaded in chitosan/β-GP hydrogels for long-term sustained and 
controlled delivery of insulin. In the in vitro release studies, only 19.11% of 
total insulin was released from the nanoparticles-loaded hydrogels within 31 
days. Most importantly, the hypoglycemic effect of nanoparticles-loaded 
hydrogel following subcutaneous injection in diabetic rats persisted for more 
than 5 days, much longer than the effect caused by free insulin-loaded 
chitosan/β-GP or other long-acting insulin formulations. Zan et al. [100] 
have found that chitosan/β-GP hydrogels influence the release profile of the 
hydrophilic drug 5-fluorouracil. The authors demonstrated that there was a 
rapid initial release of the drug because of the hydrophilic environment 
induced by the large “pores” occurred during the gel-forming process. The 
burst release of loaded drug is a commonly observed problem and drug 
release of small hydrophilic molecules is often completed in less than 24h. 
To solve this problem the drug could be encapsulated into carriers and 
subsequently embedded in the thermo-gelling matrix. Hsiao et al. [101] have 
proposed a chitosan based nanoscale drug-carriers by using amphiphilic 
chitosan obtained from carboxymethyl-exanoyl chitosan. The 
carboxymethyl-exanoyl chitosan demonstrated to self-assemble into 
nanocapsules of about 200 nm in size in aqueous environment and to form 
thermo-gelling solutions when mixed with glycerol and β-GP. 
Tissue engineering applications  
Tissue engineering is the technology of remodeling of living organism in 
vitro and involves architecture of artificial cellular scaffolds, which mimic 
the extracellular matrix. The materials used in tissue engineering must be 
biocompatible, non-toxic and have proper mechanical properties. Being an 
osteogenic medium supplement, β-GP is used in bone tissue engineering in 
form of hydrogel with chitosan. Injectable chitosan/β-GP hydrogels have 
been prepared with dexamethasone/recombinant human bone morphogenetic 
protein loaded hydroxyapatite nanoparticles [102]. The results showed that 
hydroxyapatite nanoparticles could be dispersed homogeneously in the 
matrix of chitosan/β-GP hydrogels and the combination of dexamethasone 
and recombinant human bone morphogenetic protein could promote the 
proliferation and osteoblastic differentiation of mesenchymal stem cells. 
Huang et al. [103] have prepared thermosensitive and biomimetic gel 
scaffols from chitosan, β-GP, nano-hydroxyapatite and collagen. The formed 
gel acted as a biocompatible substrate for the proliferation of rat bone 
marrow stem cells in vitro. The injected cells survived in the chitosan/β-
GP/nanohydroxyapatite/collagen for 28 days in vivo. The gels loaded with 
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bone marrow stem cells induced less inflammatory reaction in the host tissue 
than that of the cells without rat bone marrow stem cells. Liu et al. [104] 
synthesized a thermosensitive hydrogel composed of chitosan and αβ-GP 
used as basic substrate for primary culture and subculture of lymphoid cells 
from shrimp, Penaeus chinensis. The peroxidase activity indicated that cells 
seeded on the hydrogel suffered less than cells suspended in control culture 
flasks. The higher relative viability and alkaline phosphatase activity of 
primary cultured lymphoid cells indicate that chitosan/αβ-GP hydrogel 
enhances the growth and proliferation of lymphoid cells. 
 
1.9 GASTOINTESTINAL	TRACT		
In humans, the gastrointestinal (GI) tract is a long tube with muscular walls 
comprising four different layers: inner mucosa, submucosa, muscolaris 
externa and the serosa. The GI tract can be divided into an upper and a lower 
tract. The upper GI tract consists of the mouth, pharynx, esophagus and 
stomach, the lower tract comprises the small and the large intestine and the 
anus. The small intestine is the major site for the absorption of nutrients and 
drugs. This is accomplished through the enormous surface area available in 
this organ. The surface area is about 33 m2 and this value increases to ~ 120 
m2 with the villi and microvilli extensions. Enterocytes (absorptive) and 
goblet cells (mucus secreting) cover the villi. Mucus plays an important role 
in the GI tract. In fact, mucus aids the transport of chime from the gut to the 
colon by serving as a lubricant during the peristaltic process while allowing 
rapid entry and exit of nutrients and waste [46,47]. On the surfaces of 
internal organs, mucus serves as a lubricant to minimize friction between 
organs. In performing its numerous functions, mucus is continuously 
secreted, shed and finally digested, recycled or discarded. 
1.9.1	GI	Mucus	
Mucus is a complex hydrogel composed of proteins, carbohydrates, lipids, 
salts, antibodies, bacteria and cellular debris. Its physical behavior is non-
Newtonian with high variable properties that are between those of a viscous 
liquid and an elastic solid. The main protein component of mucus are 
mucins, which can be secreted or cell-bound. Mucins are primarily 
responsible for the gel properties of mucus [48], but its viscoelasticity is 
regulated also by water, lipid and ion content [49]. The viscoelastic 
properties of GI mucus are essential for its protective and lubricant 
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properties. To protect the mucosal epithelium, there is a constant turnover of 
the adherent layer and the glycocalyx in the GI tract that serves to remove 
potentially damaging compounds and organisms introduced through the diet. 
Therefore, a regulated balance occurs between mucin synthesis, degradation 
and removal, which affect the overall thickness of the mucus barrier. 
1.9.1.1	Barrier	and	protective	properties	of	GI	mucus	
The question of how the stomach is able to digest food without digest itself 
is one of the clearest examples of dynamic barrier properties of mucus 
secretions. The gastric mucosa sustains a gradient from pH 1-2 to pH 7 over 
a mucus thickness of only about 200 µm. To maintain this gradient, gastric 
mucus acts as a selective barrier to diffusion of acid, based on interactions 
that change depending on pH. Above pH 4, acid secreted by parietal cells of 
the stomach causes channels in the mucus layer, allowing acid to quickly 
reach the lumen and re-acidify the contents for optimum digestive and 
antimicrobial activity. Below this pH, mucus slows acid diffusion [50] and 
continuously secreted bicarbonate ions neutralize acid before it reaches the 
epithelium. The constant presence of acids and enzymes in the stomach 
degrades mucus, which must be counterbalanced by continual mucus 
secretion [48]. Remarkably, an adult human secretes ~10 L of water in the 
GI tract per day, of which 9.8 L are reabsorbed [46].  Reabsorption of this 
water greatly increases transport and absorption of nutrients and small 
particles that can penetrate the mucus that is continuously secreted by the GI 
tract [51]. Lubrication is another important protective property of mucus in 
GI tract. Mucus maintains an unstirred adherent layer throughout the GI. 
This layer adheres firmly to epithelium through interaction with glycocalyx. 
Mucus also traps pathogens and foreign particles via non-specific 
interactions such as hydrophobic interactions [52]. 
 
1.10 ANATOMY	OF	THE	EYE		
The human eye is approximately 24 mm in diameter and occupies about 
25% of the volume of the orbit. In the human eye, three layers can be 
distinguished (Fig. 5 [53]). The outer region consists of the cornea and the 
sclera. The cornea refracts and transmits the light to the lens and the retina 
and protects the eye against infection and structural damage. The sclera 
forms a connective tissue coat that protects the eye from internal and 
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external forces and maintains its shape. The cornea and the sclera are 
connected at the limbus. The cornea is the most anterior part of the eye, in 
front of the iris and the pupil. It is the most densely innervated tissue of the 
human body and most corneal nerves are sensory nerves, derived from the 
ophthalmic branch of the trigeminal nerve [54]. Five layers can be 
distinguished in the human cornea: the epithelium, Bowman’s membrane, 
the lamellar stroma, Descemet’s membrane and the endothelium. The 
surface of the corneal epithelium is covered by the tear film, which protects 
the corneal surface from chemical, toxic or foreign body damage and from 
microbial invasion and smoothes out micro-irregularities of the surface of 
the epithelium [55]. It consists of an outer lipid layer and an inner water-
mucous layer. The mucous layer interacts with the epithelial cells allowing 
the tear film to spread with each eyelid blink. 
A transparent mucosa membrane, the conjunctiva, covers the visible part of 
the sclera. The middle layer of the eye is composed of the iris, the ciliar 
body and the choroid. The iris controls the size of the pupil and thus, the 
amount of light reaching the retina; the ciliar body controls the power and 
shape of the lens and it is the site of aqueous production; the choroid is a 
vascular layer that provides oxygen and nutrients to the outer retinal layer. 
The inner layer of the eye is the retina, a complex, layered structure of 
neurons that capture and process the light. The retina is protected and held in 
the appropriate position by the surrounding sclera and cornea. It receives its 
blood supply from two circulatory systems: the retinal and the choroidal 
blood vessels [56,57]. The retinal circulation supplies the inner retina; the 
outer avascular retina receives their nutrients by diffusion from the choroidal 
vessel. Retinal function depends on several factors, including the region of 
the retina being illuminated, the wavelength and intensity of the light 
stimulus and the state of light adaptation. 
The three transparent structures surrounded by the ocular layers are the 
aqueous, the vitreous and the lens. 
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1.10.1	Ocular	barriers	
Several membranes and barriers control the transport of fluid and solutes in 
the eye. These barriers can interfere with the delivery of topical ocular drugs 
(e.g. eye drops) and systematically administered drugs.  Eye drops are the 
most frequently used dosage form for treating ocular diseases. For these 
drugs the first barrier to cross is the tear film, which rapidly removes 
instilled compound from the eye, resulting in low bioavailability. Other 
membranous barriers are located in the cornea, the conjunctiva, the iris-
ciliary body and the retina [58,59]. 
 
1.10.1.1	Tear	film	
A structure and composition of the tear film was proposed by Wolff [60] 
from histologic studies of the eye surface and observations of the tear film 
with a slit lamp. The film seemed to be composed of three layers: a lipid 
Fig.5: Schematic illustration of the structure of the eye  
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layer at the air surface; a middle aqueous layer and a mucus layer on the 
epithelial surface (Fig.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
McDonald [61], using the colored interference fringes formed in reflected 
white light, measured the surface lipid layer to be less than 0.5 µm. Nichols 
[62], using electron microscopy of frozen sections, measured the inner 
mucus layer in guinea pigs to be 1 µm. Holly [63] proposed a mucus 
concentration gradient, with concentration rising near the epithelium and 
becoming more diluted toward the film surface. These measurements of tear 
film, mucus and lipid thickness have established that the film is about 7 µm 
thick and is a three-layered structure in which free aqueous fluid is the main 
component.  
Fig.6:	Cross-sectional	view	of	the	tear	film	[64].			
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Subsequent, studies by Prydal et al. [64], using interferometry supplemented 
by confocal microscopy, indicated a total thickness in the region of 40 µm. 
Experiments employing acetyl cysteine to remove the mucin suggested that 
the film tear thickness was made up of a mucin layer of about 30 µm with an 
aqueous layer of about 10 µm. Mucin performs several key roles at the 
surface of the eye, of which the most important is to lower the surface 
tension of the tears. In addition, it is responsible for the high non-Newtonian 
viscosity of the tear film. 
 
1.10.2	Aqueous	humor	
The cornea and the crystalline lens, being transparent and avascular, depend 
for their nutrition on a transport medium, the aqueous humor. Aqueous 
humor also permits inflammatory cells and mediators to circulate in the eye 
in pathological conditions, as well as drugs to be distributed to different 
ocular structures [65]. 
The aqueous humor provides a transparent and colorless medium between 
the cornea and the lens. It is secreted by the ciliary epithelium and enters the 
posterior chamber. Initially, to reach the posterior chamber, the various 
constituents of aqueous humor must traverse the three components of the 
ciliary process: the capillary wall, stoma and epithelial barrier. Then, it flows 
around the lens and through the pupil into the anterior chamber. The aqueous 
humor leaves the eye by passive flow via two pathways at the anterior 
chamber angle, anatomically located at the limbus. The conventional 
pathway consists of aqueous humor passing through the trabecular 
meshwork (the structure that overpasses the scleral sulcus and converts it 
into a circular canal called Schlemm’s canal), across the inner wall of 
Schlemm’s canal, into its lumen and into draining collector channels, 
aqueous vein and episcleral veins [66,67]. The non-conventional route is 
composed of the uveal meshwork and the anterior face of the ciliar muscle 
[68]. Equilibrium between the production and the drainage of aqueous 
humor is important because the disruption of aqueous outflow, usually 
through the conventional pathway, results in elevation of intra-ocular 
pressure, which is the major risk factor in the pathogenesis of glaucoma. 
 
The major components of the aqueous are organic and inorganic ions, 
carbohydrates, glutathione, urea, amino acids, protein, oxygen, carbon 
dioxide and water. Aqueous humor is lightly hypertonic to plasma in a 
number of mammalian species, except for eyes of rhesus monkey, in which 
no significant difference was observed [69]. When comparing anterior 
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chamber and posterior chamber fluids separately, no differences were found 
in osmolarity, total concentration of dissolved substances or pH [70]. 
 
 
1.11	NUTRACEUTICAL	
 
The term “nutraceutical” was coined from “nutrition” and “pharmaceutical” 
in 1989 by Stephan DeFelice [71].  According to DeFelice, nutraceutical can 
be defined as “a food (or a part of food) that provides medical or health 
benefits, including the prevention and/or treatment of disease.” However, the 
term nutraceutical, as commonly used in marketing has no regulatory 
definition. In 1994, Zeisel [72] provided two useful working definitions: 
nutraceutical and functional foods. A nutraceutical can be defined as a “a 
diet supplement that delivers a concentrated form of a biologically active 
component of food in a non-food matrix to enhance health.” A functional 
food is not a dietary supplements, but rather, it is “any food or food 
ingredient that may provide a health benefits beyond the traditional nutrients 
its contain” [73]. In particular, a dietary supplement is characterized as 
follows: (1) it is a product, intended to supplement the diet, that bears or 
contains a vitamin, a mineral, an herb or other botanic, an amino acid or 
combinations of these ingredients; (2) it is intended for ingestion in pill, 
capsule, tablet or liquid; (3) it is not represented for use as a conventional 
food or as the sole item of a meal or diet, (4) it includes products such as an 
approved new drug, certified antibiotic. Nutraceuticals are endowed with the 
following properties: (1) they not only supplement the diet, but also aid in 
the prevention and/or treatment of disease and/or disorder; (2) they are 
represented for use as a conventional food or as the sole item of meal or diet.  
The literature on functional foods is vast and growing exponentially but the 
most important examples are: polyphenols and flavonoids, soy isoflavones, 
carotenoids, fish oils, nuts, probiotics and prebiotics. 
 
Polyphenols and flavonoids 
The term polyphenols encompasses simple phenols and flavonoids, which 
are found in fruits, vegetables and nuts and their products and posses 
important antioxidant activity. Flavonoids include proanthocyanidins, 
quercitin and ephicatechin, found mainly in chocolate, tea and wine. Red 
wine also contains resveratrol, an antioxidant product of grape skins. The 
“French paradox” refers to the epidemiologic finding that the incidence of 
	 25	
coronary heart disease was significantly lower in wine-drinking regions of 
France than in areas where wine was not the main alcoholic beverage [74]. 
Subsequently, it was shown that wine phenols inhibited the oxidation of 
low-density lipoprotein (LDL) [75], an accepted reason for the preventive 
effect of polyphenols on the development of atherosclerosis. More recently, 
it was demonstrated that the attenuation of coronary heart disease risk in 
wine drinkers is probably due as much to their lifestyle consumption of high 
amounts of polyphenol-containing fruits and vegetables as to wine [76]. 
Felice et al. [77] demonstrated that the use of polycationic chitosan 
derivatives promotes the absorption of polyphenols across the intestinal 
epithelium, thus increasing their bioavailability and potential value in 
contrasting atherosclerosis.  
 
1.11.1	Delivery	systems	for	nutraceuticals	
The delivery of nutraceuticals requires food formulators and manufacturers 
to provide protective mechanisms that 1) maintain the active molecular form 
until the time of consumption and 2) deliver this form to the physiological 
target within the organism. Polymer-based delivery systems that trap 
molecules of interest within networks have been developed extensively for 
the biomedical and pharmaceutical sectors to protect and transport bioactive 
compounds to target function [85]. Despite the successful elaboration of 
many synthetic polymers as delivery systems, these cannot be used in food 
applications that require compounds generally recognized as safe. 
 
Protein hydrogels 
Over the past decade, hydrogels have been studied extensively, due 
primarily to their ability to protect drugs from hostile environmental stimuli 
such as pH and temperature [86]. In the food industry, the use of food 
proteins to develop environment-sensitive hydrogels for nutraceutical 
delivery represents an interesting strategy. A fundamental advantage of this 
approach is that nutraceutical carrier gels can stabilize food texture, which is 
a highly desirable characteristic in the manufacturing of food products. 
Moreover, the presence of acid (e.g. carboxylic) and basic (e.g. ammonium) 
groups in polypeptide chains, which either accept or release protons in 
response to changes in pH of the medium, allows the release rate of 
molecules from protein gels to be modulated by pH variations.  
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Microparticles 
Protein-based microparticles have found wide and rapidly increasing 
applications in the food industry because they can be designed for use in 
many food formulations and virtually any ingredient can be encapsulated, 
whether hydrophobic, hydrophilic or even microbal. Chen and Subirade [87] 
prepared alginate-whey protein microspheres by an emulsification/internal 
cold gelation method. The distribution of the whey protein microparticles, of 
diameter ranging from 3-10 µm, was homogeneous within an alginate 
matrix. The method was based on the release of calcium ions from an acid 
soluble calcium salt in emulsified pre-denatured protein solution. This was 
achieved by acidification with an oil soluble acid, which partitions to the 
dispersed aqueous phase, releasing soluble calcium and initiating gelation. 
This method can be used to produce small diameter proteins beads in large 
quantity. By controlling emulsifications conditions, for example by 
modifying the dispersive forces in the emulsion formation process or adding 
a surfactant to lower the interfacial tension between the water and the oil 
phase and stabilize emulsion droplets against coalescence, the bead size can 
be controlled. Guérin et al. [88] prepared protein-alginate composite 
covalently bound by a transacylation reaction. The reaction involves the 
formation of amine bonds between protein and alginate producing a 
membrane on the bead surface, which resists gastric pH and pepsin activity. 
It was demonstrated in this study that bifidobacteria immobilized in a mixed 
gel were more resistant to stimulate human GI tract conditions. 
 
Nanoparticles 
Due to their subcellular size, nanoparticles offer promising means of 
improving the bioavailability of nutraceutical compounds, especially little 
soluble substances such as functional lipids (e.g. carotenoids, phytosterols), 
natural antioxidants and numerous other compounds that are widely used as 
active ingredients in various food products. They can prolong compound 
residence time in the GI tract by decreasing the influence of intestinal 
clearance mechanisms and increasing the surface available to interact with 
the biological support [89]. Nanoparticles can also penetrate into tissue 
through fine capillaries, cross the epithelial lining fenestration (e.g. in the 
liver) and are generally taken up efficiently by cells [90], thus allowing 
efficient delivery of active compounds to target sites in the body. Among the 
various natural or synthetic polymer-based nanoparticulate systems 
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potentially available to the food industry, protein-based nanoparticles are 
particularly interesting because they are relatively easy to prepare and their 
size distribution can be monitored. Coating nanoparticles with proteins can 
modify the adhesive properties of nano carriers and their behavior in the GI 
tract because some proteins are able to bind specifically to sugar-residues-
bearing sites located at the surface of epithelial cells [91]. β-lactoglobulin 
(βlg) coated chitosan nanoparticles have been developed by Chen and 
Subirade [92] by ionotropic gelation of chitosan and βlg mixture with 
sodium tripolyphosphate. The coating ability of βlg, studied using native 
globular and heat denatured forms, was found to be sensitive to formulation 
pH. Protein absorption appeared to be due to electrostatic, hydrophobic and 
hydrogen bonding interactions between βlg and chitosan. A pepsin 
degradation assay revealed that native βlg coating resists acid and pepsin, 
unlike denatured ones. This property is attributable to the hydrophobic 
amino acids of native βlg being hidden inside its calyx-like globular 
structure, given that pepsin preferentially attacks peptide bonds involving 
hydrophobic aromatic amino acids. Under simulated intestinal conditions, 
the βlg coatings were degraded by pancreatin. Due to its mucoadhesive 
nature, the chitosan core should adhere to the intestinal wall to facilitate the 
absorption of the nutraceutical compounds. Leclerc et al. [93] obtained a 
monodisperse suspension of 40 nm whey protein nanospheres, by modeling 
parameters affecting the thermal aggregation process. The potential of these 
nanospheres as carriers for oral administration of nutraceutical agents was 
studied in vitro by monitoring the interaction between fluorochrome-labeled 
nanospheres and Caco-2 cells. It was demonstrated that nanospheres were 
not able to adhere to the cell surface but were also visible within cells. These 
experiments suggest that whey protein nanoparticles could be internalized by 
cells and degraded therein to release the nutraceutical compounds, 
significantly improving nutraceutical compound bioavailability while 
avoiding undesired toxic side effects of the free compounds.   
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2.	EXPERIMENTAL	SECTION	
 
Various chemical modifications of chitosan have been studied in order to 
improve its solubility and applications. Attempts to introduce positive 
charge on the polymer chain appeared to be rational. Moreover, the 
introduction of thiol groups on the unsubstituted primary amino groups of 
chitosan-ammonium quaternary conjugates, led to water-soluble thiomers. 
The thiol groups are supposed to give exchange reactions with disulfide 
bonds within the mucus or oxidation reactions with cysteine-rich 
subdomains of mucus, both resulting in the formation of disulfide bonds, 
which improve the polymer mucoadhesivity. Nanoparticles prepared from 
this type of chitosan derivatives were supposed to be themselves 
mucoadhesive and apt to make nanocarriers for drug delivery.  
In the light of the above information, in this thesis, different pharmaceutical 
applications of chitosan and its derivatives, and nanoparticles based on these 
polymers have been evaluated.  
In this chapter each section presents a specific application of chitosan or its 
derivatives, or nanoparticles based on these polymers and will be divided 
into: introduction, materials and methods, results, discussion and 
conclusions.  
 
 
2.1	MUCOADHESIVE	NANO-SIZED	SUPRAMOLECULAR	
ASSEMBLIES	FOR	IMPROVED	PRE-CORNEAL	DRUG	RESIDENCE	
TIME	
 
It is now well known tat the bioavailability of ocular drugs topically 
administered by eye-drops, the most popular vehicles, is inherently poor 
because the precorneal area, which is the site of drug action/absorption, is 
rapidly cleared by natural protective mechanisms of the eye, such as 
blinking, basal and reflex tearing and nasolacrimal drainage. A classic 
approach to increasing ocular bioavailability has been the reduction of 
drainage rate by increasing the viscosity of the preparation [105,106]. More 
recently, the use of mucoadhesive polymers that do not increase the 
viscosity of the eye-drops has gained ground [107, 108, 109], mainly 
because fluid solutions are better tolerated than viscous ones [110]. A 
mucoadhesive polymer is expected to reduce the drug drainage rate, when it 
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is able, besides adhering to the ocular surface, to also bind the drug 
molecules to specific complexation sites on the polymer [108,109]. 
Nevertheless, a significant drug-polymer binding, although helpful, is no 
prerequisite for a mucoadhesive polymer ability to reduce the dug drainage 
rate. Indeed, mucoadhesive polymers, being hydrophilic, are expected to 
retain/stabilize tear fluid on the eye surface, thereby slowing down drainage 
and ultimately prolonging pre-corneal drug residence. The free, unbound 
drug molecules can diffuse in the tear film and be removed from the pre-
corneal area. Yet, this diffusion flux is likely to be significant slower the 
convective drainage that occurs in the absence of the polymer [108,109]. 
Another interesting approach to prolonging the presence of a drug on the eye 
surface and realizing an intimate contact with it has been the use of drug-
loaded polymeric and lipid nanoparticles, the applications and advantages of 
which have recently been reviewed by Almeida et al. [17]. A recent report 
deals with the development of an acetazolamide-loaded, pH-triggered 
polymeric nanoparticulate in situ gel, enhancing the conjunctival permeation 
of the drug and the pre-corneal residence time in the formulation by 
overcoming the limitations of protective ocular barriers [111]. Another 
review article by Almeida et al. [112] highlights several benefits for the use 
of chitosan for the production of polymeric nanoparticles, such as exvellent 
tolerance after topical application, bioadhesive properties, hydrophilicity, 
good spreading over the entire cornea, antimicrobial and wound-healing 
properties, pseudoplastic and viscoelastic behavior, which are desirable for 
ocular drug administration. Other characteristics of chitosan and its 
derivatives include an action to enhance trans-corneal drug permeation by 
opening the tight junctions between cells, or by intracellular routes, or 
through a mechanism based on the positive charges of the polymer, which 
interact with the cell membrane, resulting in a structural reorganization of 
tight junction-associated proteins [40,112]. Chitosan can develop hydrogen 
bonds or ionic interactions between its positively charged amino groups and 
the negatively charged sialic acid residues of mucins, depending on 
environmental pH [112]. In fact, Ameeduzzafar et al. [113] observed, 
through gamma scintigraphy, that carteolol-loaded chitosan nanoparticles 
were retained on the rabbit ocular surface significantly longer than the drug 
administered as aqueous solution. This was ascribed to the electrostatic 
interaction between the positively charged chitosan nanoparticles and the 
negatively charged ocular surface. Gamma scintigraphy was also used by 
Akhter et al. [114] to show that a chitosan coating on PLGA nanoparticles 
medicated with ganciclovir prolonged the retention of the nanoparticles on 
the rabbit corneal surface, allegedly due to the interaction of the positively 
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charged chitosan with the negatively charged corneal surface. However, it 
should be borne in mind that the positive charge is bestowed on chitosan by 
the primary amino group of its repeating unit, in a range of environmental 
pH values where it is protonated. This does not occur at the physiologic pH 
of the eye (pH 7.4), where the amino group is unionized. Therefore, to allow 
the formation of strong ionic bonds with the ocular surface, the nanoparticles 
should be prepared from polymers carrying fixed, pH-independent positive 
charges. In our laboratories, efforts have been made to prepare such a type of 
nanoparticles. The basic polymer was still chitosan, only the MW of the 
commercial product (590 kDa, according to Zambito et al. [115]) was 
reduced by oxidative depolymerization [116,117] to obtain a chitosan with a 
viscometric MW of 32 kDa (rCh). This was transformed into a quaternary 
ammonium–chitosan conjugate, coded QA-rCh60, to which, successively, 
thiol groups were covalently attached to obtain QA-rCh60-SH [115]. Both 
QA-rCh60 and QA-rCh60-SH carried fixed, pH-independent positive 
charges, in the form of quaternary ammonium ions, which were responsible, 
along with thiol groups, for the mucoadhesive properties shown by these 
chitosan derivatives [115]. In the same study, Zambito et al. prepared 
mucoadhesive nanoparticles, having positive zeta-potential, by ionotropic 
gelation of QA-rCh60-SH with hyaluronic acid (rHA), depolymerized, 
according to Shu et al. [118], to a MW of 470 kDa (viscometric). In the light 
of the above information, in the present study, we felt it intriguing to 
compare the value of mean residence time (MRT) of drug in the rabbit pre-
corneal area, determined after instillation of a drug solution containing the 
positively charged mucoadhesive polymer QA-rCh60, or QA-rCh60-SH, 
with that for drug loaded nanoparticles prepared from the same polymer. 
This comparison would clarify the actual advantages of formulating nano-
structured aggregates of specific chitosan derivatives, rather than simple 
solutions of these non-aggregated polymers, to enhance the contact time of 
drugs administered by eye-drops. The corticosteroid dexamethasone 
phosphate (DP), commonly used to treat external eye inflammation, was 
chosen as a model drug to this purpose. Another challenge that could be 
taken up with the aid of nanoparticulate systems is the improvement of the 
bioavailability of peptide drugs in the anterior segment of the rabbit eye. 
This is particularly poor because these drugs are liable to enzymatic 
degradation by peptidases present in such tissues and tears [119,120]. 
Specifically, short chain peptides, such as enkephalins, are susceptible to 
enzymatic degradation in the corneal epithelium, iris–ciliary body, and 
conjunctiva. Hence, they need anti-metabolic protection in these tissues that 
encapsulation by polymeric nanoparticles could grant. The ability of QA-
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rCh60 and QA-rCh60-SH-based nanoparticles to protect met-enkephalin 
(ME) from degradation in the rabbit pre-corneal area has been tested in the 
present study. ME is an endogenous opioid pentapeptide that can potentially 
be used in ophthalmology. Indeed it was reported that intraocular opiate 
receptors are involved in the regulation of intraocular pressure in animals 
and humans [121]. The MRT of ME, administered to rabbits via a solution 
containing QA-rCh60 or QA-rCh60-SH, was compared with that for a 
dispersion of ME-loaded nanoparticles prepared from each of these 
polymers and that for a polymer-free aqueous ME solution. To investigate 
all factors influencing the MRT values, the in vitro reversible ME binding to 
QA-rCh60, QA-rCh60-SH, or the relative nanoparticles was determined by 
the dynamic dialysis method. It must be recognized that the pre-corneal 
clearance determined in rabbits is not representative of that in humans, 
mainly because of differences in blinking frequency [122,123,124,125]. 
Such differences may bring about differences in shear thinning of tear film, 
mucoadhesion of polymer, and ultimately drainage of drugs. Nevertheless, 
since the effects of blinking can be considered similar for the different 
preparations tested, the rabbit model can be deemed robust for the 
comparative purposes of the present study. 
 
 
2.1.2	MATERIALS	AND	METHODS	
 
2.1.2.1 Materials 
Dexamethasone 21-phosphate disodium salt (DP) and met-enkephalin 
acetate (ME) were from Sigma-Aldrich (St. Louis, MO). Reduced–MW 
chitosan (rCh, viscometric MW 32 kDa) and hyaluronic acid (rHA, 
viscometric MW 470 kDa) were prepared by Zambito et al. [115]. The 
quaternary ammonium–chitosan conjugate, QA-rCh60, and thiolated 
derivative, QA-rCh60-SH, were synthesized from rCh and characterized for 
their chemical structures by Zambito et al. [115]. All aqueous 
solutions/dispersions were prepared with freshly distilled water. All other 
chemicals and solvents were of reagent grade. 
 
2.1.2.2 Preparation of medicated nanoparticles 
Nanoparticles based on QA-rCh60 (NP-QA-rCh60) or QA-rCh60- SH (NP-
QA-rCh60-SH), medicated with DP, self-assembled upon gradual addition 
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of 100 mL portions of a 350 mL volume of 0.025 mg/mL rHA and 18.85 
mg/mL DP, in phosphate buffer pH 7.4 (PB) 0.13 M (isotonic) or 0.026 M, 
to 5 mL of 2 mg/ml QA-rCh60 or QA-rCh60-SH in the same buffer. The 
final DP concentration in the nanoparticle dispersion was 1.32 mg/mL. The 
same procedure was used to prepare ME loaded NP-QA-rCh60 or NP-QA-
rCh60-SH, only the total volume of rHA in PB added to the solution of each 
chitosan derivative was 450 mL and the ME concentration in this volume 
was 2.23 mg/mL. The final ME concentration in the nanoparticle dispersion 
was 0.2 mg/mL. Following preparation, the nanoparticles were checked for 
size and zeta-potential (Zetasizer Nano ZS90). Their drug entrapment 
efficiency (EE) was evaluated by subjecting the dispersion to centrifugation 
(28 800 rpm, 1 h at 4 C), and analyzing the supernatant for the drug by 
HPLC. EE was expressed as follows: 
EE = (Mt−Ms) ⁄ Mt 
where Mt is the total drug mass used for the preparation, and Ms is the mass 
found in the supernatant. 
In some cases, to obtain stable systems, the drug-loaded nanoparticle 
dispersions were lyophilized following their preparation and successive 
dialysis to remove non-encapsulated drug (VirTis adVantage, thermal 
treatment step: −35 °C for 180 min; drying cycle steps: −30 °C for 360 min; 
−10 °C for 360 min; +10 C for 240 min; +25 C for 180 min). The 
dispersions could be regenerated from the respective lyophilized products by 
adding water under gentle stirring. In each case, a water volume was added 
apt to generate an isotonic dispersion, namely, 5 mL and 1 mL of water was 
added to lyophilized products obtained from nanoparticle dispersions in 0.13 
M and 0.026 M PB, respectively. By this procedure, isotonic pH 7.4 
dispersions of different nanoparticle concentrations were obtained. Also the 
regenerated nanoparticle dispersions were checked for size and zeta-
potential. 
 
2.1.2.3 Dynamic dialysis studies 
These studies were carried out following already described procedures 
[126]. Briefly, the same porous cellulose membrane (cut-off 12.5 kDa), 
diffusion cell, and apparatus were used at the thermostat temperature of 
37°C. At t =0, 5 mL of medicated NPQA-rCh60 or NP-QA-rCh60-SH, 
freshly prepared in 0.026 M PB, was introduced in the donor compartment 
of the cell. Sink conditions were maintained in the receiving phase (100 mL 
of 0.026 M PB). Drug transport across the membrane was assessed by 
analyzing the receiving phase at intervals for the drug by HPLC. At the end 
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of each run, the particle size in the donor phase was checked. For 
comparison, kinetic data were also obtained with the same membrane and 
procedure for the plain drug solution and this solution containing 2 mg/mL 
QA-rCh60 or QArCh60-SH dissolved in 0.026 M PB. 
 
2.1.2.4 Interrupted dialysis studies 
In the interrupted dialysis experiments, the dialysis was stopped after an 
established time from the start, and the drug fraction contained in each of the 
nanoparticle matrices, nanoparticle dispersion medium, and acceptor 
medium was determined. This procedure was repeated, running the dialysis 
for different times, to construct the plots of the drug fraction in each phase 
versus time. These plots were used to adjust the dialysis to a term suitable to 
reduce the non-encapsulated drug to a minimum and make the nanoparticle 
dispersions apt to prepare ophthalmic drops. To determine the drug fraction 
in dispersion medium and calculate that in nanoparticle matrix, 
ultracentrifugation of donor phase followed by analysis of supernatant was 
carried out. 
 
2.1.2.5 Preparation of ophthalmic drops 
For administration to rabbits, each nanoparticle dispersion, prepared in 0.026 
M PB, was dialyzed for 15 h (DP-loaded nanoparticles) or 24 h (ME-loaded 
nanoparticles) using the membrane and apparatus described in the preceding 
section, to remove most of the non-encapsulated drugs, then it was 
lyophilized. Each dispersion was regenerated from the lyophilized product 
with 1 mL of water to obtain isotonic nanoparticulate eye-drops containing 
2.6 mg/mL DP (a case of DP-loaded NP-QA-rCh60) or 2.3 mg/mL DP (a 
case of DP-loaded NP-QArCh60-SH) or 0.36 mg/mL ME (a case of ME-
loaded NP-QArCh60) or 0.27 mg/mL ME (a case of ME-loaded NP-QA-
rCh60- SH). Besides, isotonic solutions in PB 0.13 M of 2 mg/mL QA-
rCh60 or QA-rCh60-SH, each medicated with 2.5 mg/mL DP or 0.3 mg/mL 
ME, and the respective polymer-free controls were prepared for instillation 
in rabbit eyes. The polymer solutions showed viscosity values, measured by 
a capillary viscometer (Fenske, series 50, Sigma-Aldrich, St. Louis, MO), 
not significantly different from the control. The neutral pH and isotonicity of 
ophthalmic drops were confirmed by a pH-meter (Orma Electronic, Saran, 
France) and an osmometer (Roebling, New York, NY), respectively. 
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2.1.2.6 Measurement of drug elimination kinetics from tear fluid 
Male New Zealand albino rabbits weighing 3.0–3.5 kg, maintained under 
standard stabulation conditions, were used. They were treated as prescribed 
in the ‘‘Guide for the Care and Use of Laboratory Animals’’ (NIH 
Publication no. 92-93, revised 1985). All experiments were carried out under 
veterinary supervision, and the protocols were approved by the Ethical 
Scientific Committee of the University of Pisa. The medicated ophthalmic 
drops, prepared as described in the preceding section, were tested. One drop 
(50 µL) of each formulation was instilled into the lower conjunctival sac by 
a Gilson pipette with care to avoid spillage. Tear fluid samples were 
collected at various intervals from the lower marginal tear strip using 1.0 µL 
disposable glass capillaries (Microcaps, Drummond Scientific Co., 
Broomall, PA), which were flushed with 1.0 µL of water. After further 
dilution with 100 µL of water, the samples were analyzed for the drug by 
HPLC. 
 
2.1.2.7 Analytical methods 
The quantitative analysis of either DP or ME was carried out by HPLC. The 
apparatus (Perkin-Elmer, Milano, Italy) consisted of a Series 200 pump, 20 
µL Rheodyne injector, UV detector, and Turbochrom Navigator HPLC 
software (PerkinElmer, Inc., Waltham, MA) for data integration. For DP, a 
Luna 5u NH2 100 A, 250 × 4.6 mm, 5 mm column was used. The mobile 
phase (flow rate 1 mL/min) was potassium phosphate buffer pH 2, 0.02 
M/acetonitrile (60:40) and the UV detection was set at 242 nm. For ME, an 
Aquapore OD-300 (Sigma, St. Louis, MO), 250 × 4.6 mm, 7 mm column 
was used. The mobile phase (flow rate 1.2 mL/min) was 
water/methanol/trifluoroacetic acid (75:25:0.1) and the UV detection was set 
at 214 nm. Standard curves were constructed by analyzing six standard drug 
solutions in the respective eluents. All standard curves produced on different 
days were linear (r2 > 0.995) in the 2–20 mg/mL concentration range for DP 
(limit of determination, about 2 µg/ mL), and the 0.8–10 mg/mL 
concentration range for ME (limit of determination, 0.8 µg/mL). The 
retention time was 12.7 min, for DP, and 9 min, for ME. The concentration 
of each unknown sample analyzed on a given day was determined using a 
standard curve produced on the same day. With either DP or ME, standard 
curves obtained with plain drug solutions, drug solutions containing 
polymers, and drug loaded nanoparticle dispersions, all were 
superimposable. 
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2.1.3	RESULTS	AND	DISCUSSION	
 
2.1.3.1 Characteristics of medicated nanoparticles immediately 
after preparation 
As shown by the data listed in Table 1 for DP-loaded nanoparticles, on one 
hand, the mean particle size was in the 300–350 nm range, irrespective of 
whether the basic chitosan derivative was thiolated or not and the dispersing 
PB was 0.13 M or 0.026 M. On the other hand, the EE shows a trend to be 
higher with the non-thiolated polymer and, for each polymer, with the higher 
molarity of the buffer. For the nanoparticles medicated with ME, prepared in 
PB 0.13 M or 0.026 M, Table 1 shows sizes significantly different, the 
higher molarity favoring the formation of smaller sizes. On the contrary, for 
a given buffer molarity, the mean size of the ME-loaded nanoparticles 
appears statistically independent of whichever polymer was used for the 
preparation. As data in the table show, the polydispersity index values for 
freshly prepared dispersions point to scarcely homogeneous particle size 
distributions. Efforts to optimize the method of nanoparticle production, so 
as to obtain mono dispersions, will be made in a future developmental work, 
as long as warranted by the results of the present preliminary one. As for the 
EE of the ME-loaded nanoparticles, this was the highest with nanoparticles 
prepared from the thiolated polymer (unlike the DP-loaded case) in the 
stronger buffer (like the DP-loaded case). All freshly prepared 
nanoparticulate systems listed in Table 1 show positive zeta potential, 
consistent with the quaternary ammonium ions carried by the constituent 
chitosan derivatives. Probably, the differences observed between the DP- 
and ME-loaded nanoparticles are due to a different influence the different 
chemical structures of the loaded drugs exerted on the supramolecular 
aggregation of the nanoparticulate systems. 
 
2.1.3.2 Characteristics of medicated nanoparticles regenerated 
from lyophilized products 
The mean particle sizes and EE values for the isotonic dispersions of 
different nanoparticle concentrations, regenerated with different water 
volumes from the lyophilized products, are listed in Table 2. As can be 
observed, for the DP-loaded system, the sizes and EE values for the more 
concentrated dispersions are significantly, although slightly, greater than 
	 36	
those for the more diluted ones and those seen in Table 1 for the freshly 
prepared ones. Conversely, in the ME-loaded case, the sizes of the more 
concentrated regenerated dispersions appear significantly smaller than the 
more diluted ones, while the EE values are substantially similar. In all cases, 
the polydispersity index values seen in Table 2 point to sufficiently 
homogeneous size distribution of the regenerated nanoparticles, according to 
PI values reported in several literature articles [127,128,129]. Also it appears 
from the data presented in Table 2 that the particle size in all cases remained 
within the nano-scale and the zeta-potential remained positive. 
 
2.1.3.4 Drug release from nanoparticles 
Drug release from nanoparticles was studied by a procedure based on the 
interrupted dialysis followed by ultracentrifigation of donor phase [130], as 
described in the Methods section. In a previous study on DP release from 
nanoparticle systems similar to the present ones [131], it was found that in 
just one hour’s time most of the drug mass was released from the 
nanoparticle matrix into the dispersion medium and in 15 h 60% (case of 
NP-QA-rCh60) or 70% (case of NP-QA-rCh60-SH) of total DP mass 
crossed the dialysis membrane to pass from donor to acceptor medium. 
Meanwhile the DP mass fraction in the dispersion medium of nanoparticles 
dropped to about 20% (case of NP-QA-rCh60) or 15% (case of NP-QA-
rCh60-SH) and about 15% of total DP mass remained steadily associated 
with the nanoparticle matrix in both NP-QA-rCh60 and NP-QA-rCh60-SH 
cases. The results of the kinetic analysis of phases, carried out in this work 
for ME loaded NP-QA-rCh60 and NP-QA-rCh60-SH, are plotted in Figure 
1. As in the previous cases of DP-loaded nanoparticles, also the present ME-
loaded ones show pronounced burst release followed by dialysis of the burst-
released drug with substantially no further release from the nanoparticle 
matrix over 24 h. In consideration of the release results reported by Uccello-
Barretta et al. [132] for DP, and in Figure 1 of this report for ME, we 
subjected the freshly prepared DP-loaded nanoparticle dispersions to dialysis 
for 15 h and the ME-loaded ones for 24 h to remove most of the non-
entrapped drug mass (60–70% of total) from the nanoparticle systems. 
Following dialysis, the nanoparticles were lyophilized for stabilization 
before preparing ophthalmic drops by regenerating the lyophilized products 
with 1 mL water each. 
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2.1.3.5 Drug-binding studies 
Dynamic dialysis data were used to assess reversible drug interactions with 
the chitosan derivatives in solution or the surfaces of the nanoparticles in 
dispersion. Similar interactions could be correlated with possible 
enhancements of the drug residence time in rabbit pre-corneal area. In a 
previous report, DP was found to reversibly bind by about 35% and 17% to 
QA-rCh60 and QA-rCh60-SH in solution, respectively, and about 30% to 
the surface of NP-QA-rCh60. No appreciable binding was found of DP to 
the NP-QA-rCh60-SH surface35. The weaker DP interaction with the 
thiolated Ch derivative, or the surface of the nanoparticles prepared from it, 
compared with the corresponding non-thiolated polymer was ascribed to the 
thiols hindering the essentially electrostatic interaction [131]. The dynamic 
dialysis data obtained in this work with ME were plotted according to the 
following equation [126,131]: 
 
ln [(Cd ⁄Cd0) × 100] =  4.605  KmFf t                 (1) 
 
where Cd is the drug concentration in donor phase at time t, Cd0 is the drug 
concentration in donor phase at time t = 0, Ff is the non-interacting to total 
drug ratio in donor phase, and Km is the dialysis rate constant. The dialysis 
data for plain ME, ME-loaded nanoparticles, and ME in the presence of each 
of the chitosan derivatives in solution, are reported as ln (Cd ⁄Cd0) × 100 
versus t in Figure 2. In the case of nanoparticles, a virtually time-
independent fraction of total ME mass appears, from Figure 1(a) and (b), to 
be entrapped within the nanoparticle matrix. In either case, the entrapped 
mass was subtracted from the total drug mass in donor compartment, to 
calculate the effective value of Cd, i.e., the concentration of the drug portion 
actually variable in time. All plots of Figure 2 are significantly linear, as 
shown by the respective r2 values, listed in Table 3. Such linearity indicates 
that in all cases Equation (1) is obeyed and Ff is actually constant with 
varying Cd and t at least over the time of dialysis. Also the slopes of log-
linear plots are listed in Table 3. For the plain drug, Ff = 1, hence, according 
to Equation (1), the slope of the relative log–linear plot is equal to the 
dialysis rate constant, Km. From here, the drug fraction reversibly interacting 
with dissolved QA-rCh60 or QA-rCh60-SH, or dispersed nanoparticle 
surface, could readily be derived from the slope of the relevant plot. The 
resulting values are listed in Table 3. From the data, it appears that the ME 
interaction with the thiolated Ch derivative, or the surface of the 
nanoparticles prepared from it, was significant whereas the interaction with 
the corresponding non-thiolated counterparts was not. This is the opposite of 
	 38	
what resulted for DP in the previous report [132], an apparent consequence 
of the structural differences between ME and DP. 
 
2.1.3.6 Drug residence in rabbit tear fluid 
The eye-drops instilled in the rabbit eyes were biocompatible and caused no 
apparent irritation signs, such as conjunctival/corneal edema and/or 
hyperemia. The concentration in tear fluid (CTF) versus time data obtained 
with the ophthalmic drops was used to calculate the mean residence time 
(MRT) of the drug in tear fluid. This parameter resulted from the ratio, 
AUMC/AUC, between the area-under-the-momentum curve (CTFt versus t 
curve) and the area-under-the-CTF versus t curve. AUMC and AUC were 
calculated by the linear trapezoidal rule between time 0 and the time when 
CTF dropped to the minimum quantifiable value. For each elimination 
curve, the corresponding MRT was calculated, thus, for each case studied, at 
least six MRT values were obtained, of which mean and SE were calculated. 
Difference significance between two means was evaluated by Student’s t-
test (p<0.05). In the CTF versus t plot, for each time interval, the mean of six 
CTF values obtained with different animals was reported. The MRT value 
relates directly to the therapeutic efficacy of topically applied drugs that 
exert their action on the eye surface, yet it is not intended to be used as a 
surrogate for evaluation of intraocular bioavailability. This, in fact, would 
require a kinetic analysis of drug concentration in the aqueous humor. 
Nevertheless, since the cornea is the primary site of ocular drug absorption, 
an increase in MRT, hence, in contact time, is thought to result in increased 
intraocular absorption, hence, bioavailability. 
 
Data	for	DP	
The MRT data for DP formulated with either the non-thiolated QA-rCh60 or 
the thiolated QA-rCh60-SH, or loaded in either nanoparticle type, i.e., NP-
QA-rCh60 or NP-QA-Ch60-SH, are found in Table 4. The relevant CTF 
versus t data are plotted in Figure 3. As can be seen in the table, in all cases, 
the MRT values are significantly higher than the control, always indicating 
significant effects of nanoparticles and non-aggregated mucoadhesive 
polymers on drug residence in pre-corneal area, and hence, on drug 
bioavailability, which were enhanced with respect to the plain drug solution. 
The strongest effect was exerted by the NPQA-rCh60 system, which showed 
an MRT significantly higher than whichever other value in the table. Indeed 
these nanoparticles, bearing positive quaternary ammonium ions on their 
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surface, underwent a strong electrostatic interaction with the negatively 
charged ocular surface, and, concurrently, with the negative DP ions, in 
compliance with the reversible binding data referred to earlier in this report. 
In addition, as already shown, a fraction of total DP mass remained steadily 
entrapped in the nanoparticle matrix. These concurrent interactions could 
explain the prolonged DP residence in the pre-corneal area, produced by the 
NP-QArCh60 system. The non-aggregated parent polymer QA-rCh60 
produced a neatly weaker effect, despite the significant binding between this 
polymer and DP. Probably, the polymer in solution, although mucoadhesive, 
was unable to adhere to the ocular surface so strongly as the nanoparticles 
derived from it. As pointed out before, the DP anions did not appreciably 
bind to the thiolated NP-QA-Ch60-SH surface. Then, although these 
mucoadhesive nanoparticles could adhere to the ocular surface, yet their 
effect on precorneal residence was weaker than that of the non-thiolated NP-
QA-Ch60, as shown in Table 4. The effect, in fact, was similar to that of the 
non-aggregated parent thiolated polymer QA-rCh60-SH, which, for its part, 
exerted a comparatively weak binding effect on DP [132]. Then it appears 
that nanoparticles are considerably more effective than the non-aggregated 
parent polymer when they concurrently adhere to the ocular surface and 
strongly interact with the drug molecules in solution. On the contrary, 
nanoparticles prepared from mucoadhesive thiolated polymer, which interact 
weakly with the drug, are approximately as effective as the non-aggregated 
parent polymer. The data plotted in Figure 3 (a) and (b) for the systems 
based on QA-rCh60 and QA-rCh60-SH, respectively, show an apparent 
difference between the polymeric systems, aggregated or not, and the 
control. Indeed, while the latter shows a continuous CTF decrease down to 
the minimum quantifiable value, in the presence of whichever polymer or 
nanoparticle type the CTF versus t plots, following an initial drop, stabilize 
on a plateau before ending up. It is thought that the plateau corresponds with 
the stabilization of the drug in tear film, produced by either the nanoparticles 
or the parent mucoadhesive polymers. 
 
Data	for	ME	
In vivo data for the peptide ME, parallel to those discussed in the preceding 
section for DP, are listed in Table 4 and plotted in Figure 4. As can be seen 
in the table, the MRT values for the eyedrops formulated with QA-rCh60 or 
QA-rCh60-SH in solution are not significantly different from the control, in 
striking contrast NP-QA-rCh60-SH appears from the table to be strong while 
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that to NP-QA-rCh60 is insignificant, yet, the MRT values for these 
systems, found in Table 4, are not significantly different. 
	
2.1.4	CONCLUSIONS	
 
Positively charged nanoparticles able to adhere to the ocular surface, 
containing steadily associated DP or ME, have been prepared from 
mucoadhesive quaternary ammonium–chitosan conjugate and thiolated 
derivative thereof. The ability of nanoparticles to prolong the DP or ME 
residence in rabbit tear fluid following topical administration by ophthalmic 
drops has been compared with that of the non-aggregated mucoadhesive 
parent polymers. The comparison has shown that the nanoparticles are 
considerably more effective than the parent mucoadhesive polymer when 
they concurrently adhere to the ocular surface and strongly interact with the 
drug molecules in solution. This was the case with the nanoparticulate 
system based on the non-thiolated QA-rCh60. In such cases as the just 
mentioned one, it may be worth developing the often complicated 
preparation of a stable nanoparticle dispersion. On the contrary, 
nanoparticles made from the mucoadhesive thiolated QA-rCh60-SH, which 
interacted weakly with the non-entrapped DP, were approximately as 
effective as the non-aggregated parent polymer. In these cases, the 
preparation of the medicated polymer solution is a simpler, hence, more 
convenient way to prolong corneal contact time. Quite different is the 
situation with the peptide ME, the poor MRT value of which is mainly due 
to enzymatic hydrolysis. Only ME entrapment in the supramolecular 
systems NP-QA-rCh60 and NPQA-rCh60-SH was able to shield the peptide 
from aminopeptidase activity to a significant extent, whereas the non-
aggregated parent polymers were ineffective. This is a case where the 
preparation of a stable nanoparticle dispersion with significant peptide 
entrapment efficiency is a unique means of improving ocular bioavailability. 
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2.1.5	TABLES	AND	FIGURES	
 
Table 1. Characteristics of nanoparticles medicated with DP or ME 
determined immediately after preparation 
 
 Nanoparticle size, nm (polydispersity index) Zeta Potential, mV EE, % 
Nanoparticle 
type 
PB 
molarity DP ME DP ME DP ME 
NP-QA-rCh60 
0.13 314 ±53.4 (0.81±0.10) 
243.1±58.2 
(0.89±0.00) 12.1±0.2 12.1±0.2 27.6±4.1 20.0±2.8 
0.026 338.8±57.9 (0.82±0.01) 
343.7±32.5 
(0.76±0.10) 12.6±0.2 12.6±0.2 18.6±3.0 22.0±2.4 
NP-QA-
rCh60-SH 
0.13 346.9±52.2 (0.45±0.08) 
234.4±47.2 
(0.81±0.12) 10.4±0.3 11.5±0.2 19.1±3.3 26.3±3.5 
0.026 321.1±11.9 (0.72±0.08) 
361.3±21.5 
(0.73±0.03) 15.2±0.7 18.3±1.5 12.9±2.6 21.0±2.1 
 
Means ± SE (n=10) 
 
Table 2. Characteristics of nanoparticles medicated with DP or ME 
regenerated with water from lyophilized products. 
 
 Nanoparticle size, nm (polydispersity index) Zeta Potential, mV EE, % 
Nanoparticle 
type 
Water, 
mL DP ME DP ME DP ME 
NP-QA-rCh60 
5 313.2±16.9. (0.50±0.06) 
508.9±52.3 
(0.56±0.05) 12.3±0.2 12.1±0.8 28.1±2.5 19.8±2.4 
1 429.1±49.9 (0.38±0.01) 
367.1±37.6 
(0.38±0.04) 12.2±0.3 12.5±1.0 34.6±3.2 24.7±3.0 
NP-QA-
rCh60-SH 
5 360.9±24.7 (0.60±0.13) 
442.5±49.3 
(0.39±0.06) 12.3±0.4 11.9±0.6 18.5±2.9 22.3±2.6 
1 402.8±17.2 (0.44±0.05) 
357.1±25.9 
(0.37±0.05) 12.0±0.5 12.4±0.7 29.7±3.4 23.1±3.1 
 
Means ± SE (n=10) 
  
	 42	
 
 
Figure 1. Kinetic analysis of dialysis phase for ME loaded freshly prepared 
nanoparticles: NP-QA-rCh60 (a) and NP-QA-rCh60-SH (b). Key: , 
nanoparticle matrix; n, nanoparticle dispersion medium; p, acceptor 
medium. 
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Figure 2. Plots of dynamic dialysis data according to Equation (1). In donor 
phase, ME (0.02 mg/mL) alone (control) or in the presence of QA-rCh60 (2 
mg/mL) or NP-QA-rCh60 (freshly prepared) (a); QA-rCh60-SH (2 mg/mL) 
or NP-QA-rCh60-SH (freshly prepared) (b). 
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Table 3. Results of analysis of dynamic dialysis data for ME plotted in 
Figure 2 according to Equation (1).  
 
Binding agent Modulus of straight line slope (×102) ± SD, h-1 r
2 Interaction , % 
Control 12.5±0.7* 0.993 - 
QA-rCh60 11.7±1.2 0.965 n.s. 
NP-QA-rCh60 12.6±0.9 0.993 n.s. 
QA-rCh60-SH 10.2±0.4 0.998 18.4 
NP-QA-rCh60-SH 6.8±0.5 0.990 45.6 
 
* Dialysis rate constant 
n.s. Not significant 
 
Table 4. Mean residence time (MRT) in rabbit tears for 2.5 mg/mL or 0.3 
mg/mL ME instilled via different ophthalmic drops. 
 
 MRT, min 
Vehicle DP ME 
Control 8.62±0.75 3.3±0.3 
QA-rCh60 solution 14.77±1.92 4.5±0.5 
NP-QA-rCh60 dispersion 30.1±4.51 11.0±1.9 
QA-rCh60-SH solution 17.01±2.38 3.8±0.4 
NP-QA-rCh60-SH 
dispersion 17.5±2.80 12.5±1.3 
 
Means ± SE (n=6). 
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Figure 3. Profiles of DP elimination from tear fluid of rabbits following 
instillation of 2.5 mg/mL drug via different ophthalmic drops: QA-rCh60 
solution or NP-QA-rCh60 dispersion (a); QA-rCh60-SH solution or NP-QA-
rCh60-SH dispersion (b). 
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Figure 4. Profiles of ME elimination from tear fluid of rabbits following 
instillation of 0.3 mg/mL drug via different ophthalmic drops: QA-rCh60 
solution or NP-QA-rCh60 dispersion (a); QA-rCh60-SH solution or NP-QA-
rCh60-SH dispersion (b). 
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2.2	MUCOADHESIVITY	AND	RELEASE	PROPERTIES	OF	
QUATERNARY	AMMONIUM-CHITOSAN	CONJUGATES	AND	THEIR	
NANOPARTICULATE	SUPRAMOLECULAR	AGGREGATES:	AN	NMR	
INVESTIGATION	
 
Nanoparticulate systems are the most intriguing vehicles for systemic drug 
administration, in virtue of their potential for prolonging drug residence at 
the adsorption site and improving the bioavailability by protecting the 
entrapped drug from degradation [133]. Mucoadhesive, biocompatible and 
biodegradable polymers have usually been chosen as the basic materials, 
among which the chitosan (Ch) derivatives shown in Fig. 1 have played a 
significant role [115]. Ch is now known to act as an effective drug 
absorption enhancer [134]. Its effectiveness can be improved by partial 
quaternization [42] conjugation with quaternary ammonium ions and by 
covalent attachment of thiol-bearing compounds [115,39]. In consideration 
of the enormous technological impact of such a kind of absorption 
promoters, the availability of non-invasive methods for the evaluation of 
drugs to polymeric materials affinities becomes fundamental in 
nanoparticles production. Nuclear magnetic resonance (NMR) spectroscopy 
represents a very powerful and versatile technique for the non-invasive 
investigation of supramolecular aggregation processes and in the 
quantitative determinations. In particular, relaxation features of NMR active 
nuclei are highly sensitive indicators of the occurrence of intermolecular 
interactions, which reflect drug to macromolecules affinities [135,136]. The 
determination of the in vitro release kinetics of a drug loaded in a 
nanoparticulate system has usually been attempted to characterize the 
pharmaceutical potential of nanoparticles. The dynamic dialysis method as 
extensively been used for this purpose [137, 138, 139, 140, 141, 142, 143, 
144, 145, 146]. However, a recent study has shown that an uncritical use of 
dynamic dialysis to assess drug release from nanoparticulate systems may be 
misleading [131]. Alternatively, the great potentialities of NMR quantitative 
determination could be effectively exploited for an accurate and non-
invasive definition of release profile. Therefore, in the present work 
dexamethasone 21-phosphate disodium salt (DP, Fig. 2) was selected as 
probe for the evaluation of the affinity for quaternary ammonium–chitosan 
conjugates (QA-rCh60) and corresponding thiolated derivatives (QA-rCh60- 
SH), obtained via formation of amide bonds with thioglicolic acid [115]. The 
effect of supramolecular aggregation of the above polymers into stable 
nanoparticulate structures (NP-QA-rCh60 or NP-QA-rCh60-SH), 
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synthesized from reduced MW hyaluronic acid (rHA) and quaternary 
ammonium–chitosan conjugates (QA-rCh60 and QA-rCh60-SH), was 
evaluated by analyzing mixtures containing empty nanoparticles and DP. 
The mucoadhesive properties of nanoparticles were examined in dis- 
persions/solutions containing bovine submaxillary mucin (BSM). The 
release properties of the nanoparticles loaded with DP were investigated by 
quantitative NMR analysis. For comparison such properties were also 
investigated by the interrupted dialysis technique described by Zambito et al. 
[131], while the drug binding with the Ch derivatives, QA-rCh60 and QA-
rCh60-SH, or with the surfaces of the relevant nanoparticles, NP-QA-rCh60 
and NP-QA- rCh60-SH, was also studied by the dynamic dialysis technique, 
also described in detail by Zambito et al. [131]. 
 
2.2.1	MATERIALS	AND	METHODS	
2.2.1.1 Materials 
Bovine submaxillary mucin (BSM) and dexamethasone 21-phosphate 
disodium salt (DP) were purchased from Sigma Aldrich. Reduced MW 
chitosan (rCh) derivatives were synthesized by the materials and methods 
reported by Zambito et al. [115]. 
2.2.1.2 NMR measurements 
NMR measurements were performed on a spectrometer operating at 600 
MHz for 1H. The temperature was controlled to ± 0.1 °C. The spin-lattice 
selective relaxation rates were determined by using the inversion recovery 
pulse sequence (180°-τ-90°-t)n and by applying a selective π-pulse at the 
selected frequency. 
2.2.1.3 Sample preparation 
DP loaded (or empty) nanoparticles (250–365nm) self- assembled on 
addition of 0.25mL of aqueous 0.025mg/mL rHA containing (or not) 1.32 
mg/mL DP to 5 mL of a stirred 2 mg/mL rCh derivative solution in 
phosphate buffer pH 7.4 0.13 M, after which the dispersion was lyophilized. 
For NMR analysis the nanoparticle dispersions were regenerated in D2O 
from their lyophilizates. All of the other materials analyzed by NMR were 
dissolved in D2O (phosphate buffer, pH = 7.4). 
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2.2.1.4 Dynamic dialysis studies 
For the dynamic dialysis studies a porous regenerated cellulose membrane 
(MWCO 12 kDa, Sigma), pre-soaked at least 24 h in water was mounted 
into a dynamic dialysis cell and apparatus, described in detail by Bottari et 
al. [147]. At time t=0, 5mL of DP-loaded nanoparticles, obtained as 
described above, was placed in the donor compartment of the cell and 
stirring of donor and acceptor phases was started, while maintaining the 
thermostat temperature at 37 °C. The volume of acceptor phase (water) was 
100 mL. Drug transport across the membrane was assessed spec- 
trophotometrically by analyzing the receiving phase at intervals and 
calculating the drug fraction appeared in the receiving phase at time t. At the 
end of each run the donor was checked for mean size of dispersed 
nanoparticles. For comparison, kinetic data were also obtained, using the 
same membrane and procedure, for the plain 1.32 mg/mL drug solution and 
this solution containing 2 mg/mL dissolved QA-rCh60 or QA-rCh60-SH. 
2.2.1.5 Interrupted dialysis studies 
In the interrupted dialysis experiments the dialysis was stopped after an 
established time from the start, and the drug fraction contained in each of 
nanoparticle matrix, nanoparticle dispersion medium, and acceptor medium 
was determined. This procedure was repeated, running the dialysis for 
different times, to construct the plots of the drug fraction in each phase vs. 
time. Ultracentrifugation of donor phase followed by spectrophotometric 
analysis of supernatant was carried out to determine the drug fraction in 
dispersion medium and to calculate that in nanoparticle matrix. 
 
2.2.2	RESULTS	AND	DISCUSSION	
2.2.2.1 NMR investigation  
The selection of methods suited to investigate substrate/macromolecule 
interactions essentially depends on the need to set a very high 
substrate/macromolecule molar ratio (from 20-100 to 1 or greater), in order 
to obtain a detectable NMR signal for the ligand. On the fast exchange 
conditions, the observed parameter represents the weighted average of its 
value in the bound and free states, according to Eq. (1): 
Pobs =Pfxf +Pbxb                           (1) 
where xf and xb represent the molar fraction in free and bound state, 
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respectively. So it is clear the need to find NMR parameters undergoing a 
sharp variation as the consequence of ligand–macromolecule interaction. 
Because binding-induced chemical shift changes are relatively small 
compared to the line width changes, most NMR studies have been focused 
on different NMR parameters, such as relaxation rates [136, 109, 126, 
148,149,150,151]. It has been shown that the selective relaxation rate (Rms) 
of the ligand is a more sensitive indicator of binding than non-selective 
relaxation rate (Rns) is. In fact, methods based on the determination of the 
selective relaxation rates take advantage of the favourable dependence of 
Rms on the correlation time (τc) in the region of slow molecular motions, in 
which the small molecule is forced by the interaction with the 
macromolecule. In the fast-motion region (ω2τc2 << 0.6; ω=Larmor 
frequency), both the selective (Rms) and non-selective (Rns) relaxation rates 
increase progressively with increasing τc. When the molecular motion of the 
ligand is slowed down to the ω2τc2  >>0.6 region, as a consequence of the 
interaction with the macromolecule, Rms shows a sharp increase, whereas Rns 
reaches a maximum for ω2τc2 ≅	 0.6 and then decreases with further 
increasing of ω2τc2. In the fast-exchange limit, the measured relaxation rates 
(Robs) are the weighted average of the values in the bound (Rb) and free (Rf) 
states (Eq. (1). Further information on the drug–macromolecule interaction 
can also be extracted by cross-relaxation (σij) measurements, whose values 
can be obtained by the measurements of mono (Rims) and bi-selective (Rijbs) 
relaxation rates of a proton pair ij, and subtracting Rims from Rijbs (Eq. (2)) 
[135, 136]: 
σij = Rijbs − Rims 
In the initial rate approximation [152] the cross-relaxation terms describe the 
magnetization transfer between the proton pair, which is a very simple 
function of the reorientational correlation time τc and of their distance rij (Eq. 
(3)): 
σij = 0.1 h2rij-6τc [6/(1+4 ω2τc2)−1]  (3) 
Small and medium-size molecules are in the fast motion conditions, so they 
are characterized by positive values of σij (Eq. (4)), whereas in the case of 
interaction with macromolecules a negative value of σij is detected (Eq. (5)), 
that is typical of macromolecules or ligands bound to them. 
σij = 0.5 γ4 h2rij-6τc     (if ω2τc2 <<0.6)    (4) 
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σij = −0.1 γ4 h2rij-6τc     (if ω2τc2 >>0.6)     
 
 
So, if the macromolecule binds the drug, a decrease of σij with respect to the 
free value must be expected, the extent of which depends on the bound 
molar fraction. For our analysis, we selected the proton H1 of DP (Fig. 2), in 
consideration of its simple structure (doublet) and the fact that it was well 
separated from other proton signals and no superimposition of proton signals 
from any polymeric materials was found. The relaxation rate of pure DP was 
0.91 s-1 (Table 1), which increased to 1.46 s-1 in presence of the quaternized 
polymer QA-rCh60. A comparable increase was detected in the mixture 
containing the thiolated polymer in the same experimental conditions (DP = 
1.29 mg/mL, polymers = 6.85 mg/mL, 25 °C, D2O, pH = 7.4). The 
measurements of bi-selective relaxation rates of the proton pair H1−H2 gave 
the corresponding cross-relaxation terms, which was 0.01 s-1 for pure DP 
and became negative in the presence of the two polymers (−0.11 s-1 for QA-
rCh60 and −0.17 s-1 for QA- rCh60-SH), thus reflecting the ability of both 
polymers to interact with the drug, with a slightly higher drug affinity for the 
thiolated system with respect to QA-rCh60. The supramolecular assembly of 
polymeric materials into the nanostructured forms remarkably increased the 
affinity of DP for the two polymers, since the proton selective relaxation 
rates of proton H1 underwent a threefold increase in the presence of empty 
NP-QA-rCh60 with respect to the polymer, and a minor effect was detected 
in the presence of NP-QA-rCh60-SH. The same trend was reflected by 
cross-relaxation terms, which showed an about tenfold increase for the 
nanoparticles with respect to polymer QA-rCh60 and a threefold increase for 
the thiolated system. The presence of BSM remarkably perturbed mono-
selective relaxation rates of the drug (Table 1), and its effect was much more 
pronounced than that of the polymers: in fact, the presence of 10 mg/mL of 
BSM inside the NMR tube caused the increase of relaxation rates of proton 
H1 from the value of 0.91 s-1 up to 3.88 s-1, and the relevant affinity of DP to 
mucin was reflected in the value of the cross-relaxation term, which was 
−0.78 s-1, i.e. remarkably higher with respect to the corresponding value in 
the presence of both polymers (Table 1). The effect of mucin is more 
pronounced in the ternary mixtures containing empty nanoparticles: the 
values of −3.05 s-1 and −2.30 s-1  were obtained for cross-relaxation term in 
the presence of NP-QA-rCh60 and NP-QA-rCh60-SH, respectively. 
Therefore, the exposed surface of polymers in the nanoparticles is endowed 
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with mucoadhesive properties, thus revealing a cooperative interaction 
mechanism between mucin and both kinds of nanoparticles. By analyzing 
the release properties of loaded nanoparticles by integration of the signal of 
proton H4 (Fig. 2), we observed that a part of the drug, approximately the 
50%, at t = 0 is already on the external of the nanoparticulate structure 
(Table 2). The release of the remaining part of DP is very slow in the first 24 
h, according to the high affinity of DP for the nanoaggregates previously 
observed (Table 1) and discussed, and it is almost complete after 21 days 
(Fig. 3). The release of DP is slightly faster in the presence of NP-QA- 
rCh60-SH with respect to NP-QA-rCh60, thus suggesting that the presence 
of thiol groups somehow hinders the electrostatic attraction between the 
positively charged polymer and the negatively charged DP. The significant 
decrease in the starting concentration of DP observed in the samples 
containing mucin is probably due to the attitude of BSM to coat the external 
surface of the nanoaggregates as a consequence of the interaction with them, 
thus forming an outer film that DP has to cross. A comparison of relevant 
data in Tables 1 and 2 shows that the relaxation rates of proton H1 of DP, 
recorded at the end of the release and listed in Table 2, are more similar to 
those recorded for the mixtures containing the polymers, listed in Table 1, 
than those containing the empty nanoparticles, also listed in Table 1, 
suggesting that a loss of the nanoparticulate structure occurs at the end of the 
release. Data in Table 2 and in Fig. 3 also show that the presence of BSM 
remarkably decreased the starting concentration of DP in solution, especially 
for the sample containing NP-QA-rCh60-SH (0.3 mg/mL in comparison to 
1.4 mg/mL in absence of mucin), nevertheless also in these mixtures a 
complete release of DP was observed after 21 days. 
2.2.2.2 Analysis of release by interrupted dialysis 
The nanoparticle dialysis process was stopped at different times from the 
start and the drug fractions contained in the three different phases, namely, 
the nanoparticle phase, the nanoparticle dispersion medium (internal phase 
of dialysis), and the receiving phase of dialysis were determined at each 
stop. The changes in time of the respective drug fractions can be visualized 
in Fig. 4 a and b for NP-QA-rCh60 and NP-QA-rCh60-SH, respectively. 
Data in the figure show that in just one hour’s time most of the drug mass 
was released from the nanoparticle matrix into the dispersion medium in the 
donor phase, while only about 10% crossed the membrane into the receiving 
phase. Over 24 h of dialysis about 60% (case of NP-QA-rCh60) or 80% 
(case of NP-QA-rCh60-SH) of the drug mass passed from donor to acceptor 
medium, while no significant decrease of the drug mass entrapped in the 
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nanoparticle matrix (about 15%) could be detected. The data altogether 
confirm the quantitative NMR analysis of the signal of proton H4 indicating 
that after an initial burst the successive release is slow with both 
nanoparticle types. A slower dialysis process with NP- QA-rCh60 compared 
to NP-QA-rCh60-SH results from comparing relevant data in Fig. 4 a and b. 
This reflects a higher DP affinity for the former nanoparticle surface that 
also results from the NMR analysis. 
2.2.2.3 Study of drug interaction with nanoparticle surface by 
dynamic dyalisis 
For the assessment of such an interaction the dynamic dialysis data were 
plotted, as described by Bottari et al. [147], according to the following 
equation: 
ln [(Cd ⁄ Cd0) × 100] = 4.605 − Km Ff t      (6) 
where Cd is the drug concentration in donor phase at time t, Cd0 is the drug 
concentration in donor phase at time t=0, Ff is the non-interacting to total 
drug ratio in donor phase, and Km is the dialysis rate constant. The dialysis 
data for plain drug, drug loaded nanoparticles, i.e., NP-QA-rCh60 or NP-
QA-rCh60-SH, and drug in the presence of each of the Ch derivatives, i.e., 
QA-rCh60 or QA-rCh60-SH, are reported as ln [(Cd ⁄ Cd0) × 100] vs. t in Fig. 
5. In the case of nanoparticles a virtually time-independent fraction of total 
DP mass appears, from Fig. 4 a or b, to be entrapped within the nanoparticle 
matrix. In either case the entrapped mass was subtracted from the total drug 
mass in donor phase, to calculate the effective value of Cd, i.e., the 
concentration of the drug portion actually variable in time. All plots of Fig. 5 
are significantly linear, as shown by the respective r2
 
values, listed in Table 
3. Such a linearity indicates that in all cases Eq. (6) is obeyed and Ff is 
actually constant with varying Cd and t at least over the time of dialysis. The 
slopes of log-linear plots are listed in Table 3. For the plain drug Ff = 1, 
hence, according to Eq. (6) the slope of the relevant log-linear plot is equal 
to the dialysis constant, Km. For each case of significant drug-substrate 
interaction the respective Ff can be calculated from the ratio of the slope of 
the respective log-linear plot to the dialysis constant, Km. From here, the 
values of drug fraction reversibly interacting with dissolved QA-rCh60 or 
QA-rCh60-SH, or dispersed nanoparticle surface, can readily be derived. 
They are listed in Table 3. From the data it appears that the DP interaction 
with the non-thiolated Ch derivative, or the surface of the nanoparticles 
prepared from it, is stronger than that with the corresponding thiolated 
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substrates. Since the interaction is essentially electrostatic in nature, it is 
likely to be hindered by thiol groups. It should be stressed that DP does not 
only reversibly bind to the nanoparticle surface, in fact, a significant drug 
fraction remains entrapped inside the nanostructures, as shown in Section 
2.2.2.2. This fraction should be added to the relevant value in Table 3 to 
obtain the whole drug fraction interacting with each nanoparticle type. In the 
light of this consideration the results of the affinity studies carried out by 
NMR are in substantial agreement with those obtained by the dialysis 
method. 
 
2.2.3	CONCLUSIONS		
NMR relaxation rate measurements were confirmed powerful tools for 
detecting intermolecular interactions between drugs and macromolecules, 
with a relevant potential in the rational design of advanced materials.Both 
kinds of polymers, i.e., QA-rCh60 and its thiolated derivative, QA-rCh60-
SH, have shown remarkable affinities for DP; the exposed surface of 
polymers in nanoparticles is predisposed to interaction with the drug and 
also endowed with relevant mucoadhesivity. The analysis of release 
properties of nanoparticles showed that about half of the drug is on the 
external, and the remaining part of it is involved in very strong interactions 
inside the nanoparticles. The complete release of the drug must occur as the 
consequence of the loss of nanoparticulate supramolecular aggregation, 
since the interaction of DP with nanoparticles at the end of the release 
process is comparable with starting polymeric materials, rather than with 
empty nanoparticles. Interestingly, the presence of BSM causes a decrease 
of DP at t = 0, that can be correlated to the formation of a mucin layer on the 
nanoparticle surface, thus hindering the release of DP bound to the external 
of the nanoparticle. 
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2.2.4	TABLES	AND	FIGURES		
Figure 1. Structures of chitosan derivatives used as basic materials for 
nanoparticles. 
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Figure 2. Structure of dexamethasone 21-phosphate disodium salt. 
 
 
 
 
 
 
 
 
 
 
Table 1. Mono- and bi-selective relaxation rates (R1ms and R12bs) of H1 
proton of DP (1.29 mg/mL), 600 MHz, D2O, pH=7.4, 25°C), normalized 
relaxation rates (ΔR/Rfree, where ΔR= Rmix−Rfree) and cross-relaxation 
parameters (σ12, s-1) in different mixtures. 
 R1ms (s-1) ΔR/Rfree R12bs  (s-1) σ12 (s-1) 
DP 0.91 - 0.92        0.01 
DP + QA-rCh60 1.46 0.60 1.35      −0.11 
DP + QA-rCh60-SH 1.57 0.73 1.40 −0.17 
DP + NP-QA-rCh60 4.22 3.64 2.98 −1.24 
DP + NP-QA-rCh60-SH 2.35 1.58 1.77 −0.58 
DP + BSM 3.88 3.26 3.10 −0.78 
DP + NP-QA-rCh60 + BSM 11.82 11.99 8.77 −3.05 
DP + NP-QA-rCh60-SH + BSM 9.23 9.14 6.93 −2.30 
 
O P
O-  Na+
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Table 2. Concentration data (mM), mono- and bi-selective relaxation rates 
(R1ms and R12bs) of H1 proton and cross-relaxation parameters (σ12, s-1) of DP 
in loaded nanoparticles (600 MHz, D2O, pH=7.4, 25°C) at the end of the 
release process. 
 
DP (mM) Relaxation measurements 
t0 24h 21st day R1ms (s-1) R12bs  (s-1) σ12 (s-1) 
NP-QA-rCh60 1.1 1.6 1.8 1.71 1.57 −0.14 
NP-QA-rCh60-SH 1.4 1.9 2.1 1.71 1.53 −0.18 
NP-QA-rCh60 + BSM 0.6 1.1 1.7 4.02 3.24 −0.78 
NP-QA-rCh60-SH + BSM 0.3 0.9 1.8 1.58 1.56 −0.02 
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Figure 3. Kinetics of DP release from (a) NP-QA-rCh60, (b) NP-QA-
rCh60-SH, (c) NP-QA-rCh60 + BSM, (d) NP-QA-rCh60-SH + BSM. 
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Figure 4. Interrupted dialysis data for DP-loaded NP-QA-rCh60 (a) and NP-
QA-rCh60-SH (b). Key: NO, nanoparticle phase; DM, dispersion medium; 
RP, receiving phase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Plots of dynamic dialysis data according to Eq. (6). 
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Table 3. Binding parameters for dynamic dialysis data in Fig.5. 
 
Substrate Rate constant ± SD
a 
(×102, h-1) r
2 Interactionb , % 
Control 13.66±0.33 0.998 - 
QA-rCh60 8.94±0.16 0.999 34.55 
QA-rCh60-SH 11.34±0.07 0.999 16.98 
NP-QA-rCh60 9.61±0.32 0.997 29.65 
NP-QA-rCh60-SH 13.40±0.84 0.988 n.s.c 
 
a Modulus of straight line slope. 
b Reversibly bound drug fraction. 
c Not significant. 
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2.3	EFFECT	OF	DIFFERENT	CHITOSAN	DERIVATIVES	ON	IN	VITRO	
SCRATCH	WOUND	ASSAY:	A	COMPARATIVE	STUDY	
 
According to the Wound Healing Society, a wound is the result of 
“disruption of normal anatomic structure and function” [153] and may be 
classified as acute or chronic, on the basis of the wound healing process 
[154,155]. During this process, growth factors released from fibroblasts, 
macrophages, neutrophils, keratinocytes, and endothelial cells influence all 
phases of wound healing and act by providing signals for various cellular 
activities [154, 156]. Fibroblasts, one of the dominant components of dermal 
structure, play an important function all through the process. In fact, in the 
early stage of wound healing, they migrate to the traumatized region to 
promote the regeneration of blood vessels, extracellular matrix deposition 
and granulation tissue formation, through the release of some angiogenesis 
factors [157]. In the advanced trauma repair, a large number of fibroblasts 
mature into myofibroblasts, which promote wound closure [158,159]. 
Different strategies have been developed to make the wound healing process 
faster and less painful. Recently, numerous studies demonstrated the 
function of chitosan as a wound healing accelerator [160, 161, 162]. 
Chitosan, a polysaccharide obtained by partial deacetylation of natural 
chitin, has been widely used as a wound dressing material due to its 
properties [163]. The notable properties of chitosan include its non-toxicity, 
hemostatic action, anti-inflammatory effect, biodegradability, 
biocompatibility, antimicrobial activity, retention of fibroblast growth 
factors, and release of glucosamine [163,164]. Chitosan and its derivatives 
could accelerate wound healing by enhancing the functions of inflammatory 
cells, such as fibroblasts, polymorphonuclear leukocytes and macrophages 
[165]. The wound healing effects of chitosan could be affected by its 
physico-chemical characteristics, such as molecular weight (MW), 
deacetylation degree and derivatization [163,166]. The application of native 
chitosan is limited by non-solubility in neutral or alkaline media. Therefore, 
new forms of chemically modified chitosan have been developed in order to 
improve the beneficial properties of this biomaterial. In particular, chitosan 
derivatives soluble in aqueous neutral or alkaline media have been 
developed, such as chitosan derivatives containing quaternary ammonium 
salts [167,18] and carboxymethyl chitosan [134]. The purpose of this study 
is to compare the effects of 8 chitosan derivatives with different MWs, either 
thiolated or not, on the wound healing process. For the purpose of sparing 
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animals the in vitro scratch assay was used to assess the wound healing rate, 
following a procedure described in the literature [168]. 
 
2.3.1	MATERIALS	AND	METHODS		
2.3.1.1 Preparation of chitosan derivatives 
The commercial chitosan (Ch) had an average viscometric MW of 590 kDa 
and a deacetylation degree, determined by IR or NMR, of 90% or 82% [39]. 
Its MW was reduced by oxidative depolymerization (see, e.g., [117, 116]), to 
obtain rCh (viscometric MW, 32 kDa). The viscometric MWs of Ch and rCh 
were determined by an Ostwald U-tube capillary viscometer (Cannon-
Fenske series ASTM 75), following the procedure reported by Khalid et al. 
[169]. Quaternary ammonium–Ch or quaternary ammmmonium–rCh 
conjugates (N+-Ch or N+-rCh) were synthesized by reacting 
diethylaminoethyl chloride hydrochloride with Ch or rCh, through the 
materials and procedure described by Zambito et al. [115], keeping the pH at 
8 and controlling the temperature at 50 °C (product code, N+-Ch(50°) or 
N+rCh(50°)), or 60 °C (product code, N+-Ch(60°) or N+-rCh(60°)). 
Thiolation of N+-Ch and N+-Ch was carried out by attaching thioglycolic 
acid to unsubstituted primary amino groups still present on the polymer 
chains, via formation of amide bonds mediated by 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide [115]. The degree of acetylation (DA) of 
chitosans, the degree of substitution (DS) of the quaternary ammonium–
chitosan conjugates by pendant moieties containing quaternary ammonium 
groups, and the number of quaternary ammonium groups in substituted 
moieties (n), were determined by NMR [39]. The degree of substitution by 
thiol- bearing groups (ThDS) was determined by iodometry [170]. The 
above characteristics of chitosans and chitosan derivatives are summarized 
in Table 1. 
2.3.1.2 Cell culture and treatment 
Fibroblasts were isolated from human skin. Cells were cultured in 
Dulbecco’s modified Eagle medium (DMEM), supplemented with 10% fetal 
bovine serum (FBS), 4mM l-glutamine, 100U/ml penicillin and 100 µg/ml 
streptomycin, and incubated at 37 °C in a humidified atmosphere with 5% 
CO2. Medium was routinely changed every 3rd day and at confluence cells 
were subcultured (split ratio 1:3) by trypsinization (0.5% trypsin/0.02% 
EDTA). In all experiments cells were used between P4 and P5 passage 
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cultures. 
2.3.1.3 Cytotoxic assay 
The cytotoxicity of chitosan derivatives was examined by WST-1 assay, 
based on the cleavage of tetrazolium salt (4-[3-(4- iodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolium]-1,3-benzene disulfonate, Roche Applied 
Science, Mannheim, Germany) by mitochondrial dehydrogenases, present in 
viable cells. A stock solution of each chitosan derivative (1 mg/ml) was 
prepared by dissolving 5 mg of polymer in 5 ml of sterile water. Each stock 
solution was then diluted to 5, 10, 30, 50, or 100 µg/ml with DMEM plus 
1% FBS, the pH of which was first adjusted to 4.0, by 5 M HCl, then to 7.0 
by 6 M NaOH. Cells were seeded on a 96-well cell culture plate at a cell 
density of 2 × 103 cells/well (100 µL medium/well). After 24 h of cultivation 
at 37 °C 100 µL of each chitosan derivative solution prepared as described 
above was added to each well and incubated for further 24 h. At the end of 
the treatment cells were washed with PBS and 100 µl of culture medium 
containing 10% (v/v) WST-1 reagent (10 µl/well) was added to each well 
and incubated for 4h at 37 °C, 5% CO2. Absorbance of the medium at 
450nm was measured using a microplate spectrophotometer (Thermo 
Scientific). The absorbance directly correlated to the number of 
metabolically active cells. Absorbance was plotted as percent absorbance of 
control (culture medium without chitosan derivatives). 
2.3.1.4 In vitro scratch wound healing assay 
Fibroblasts between passages 4 and 5 were seeded in 24-well plates (12 × 
103 cells/well) and grown until confluence in complete DMEM with 20% 
FBS in a humidified atmosphere of 5% CO2. Thereafter, the procedure 
described by [168] was followed. A straight scratch was made with a P200 
pipette tip, to simulate a wound. The cell debris was removed and the edge 
of the scratch was smoothed by washing with serum free medium. The 
wound was exposed to high and low MW chitosan derivatives at the 
concentration of 10 µg/ml in DMEM with 1% serum for 24 h at 37 °C. The 
cells without treatments were used as the control. The closure of the scratch 
was observed under a microscope (5× magnification). At 0 and 24 h after 
wounding, digital images of cells were captured by a phase contrast 
microscope (Nikon) equipped with a digital CCD camera (EOS 1000D, 
Canon, Milano, Italy). To quantify the closure of the scratch the difference 
between wound width at time 0 and time 24 h was determined. Each well 
was marked below the plate surface by drawing a vertical line, to allow 
identification of the same scratched area in order to take consistent pictures. 
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Scratch area was measured using ImageJ software (National Institutes of 
Health, Bethesda, MD, USA). Migration rate was expressed as percentage of 
scratch closure on an initial area basis, according to the following equation: 
Scratch closure rate = [(At0−At)/At0] × 100 
where At0 is the scratch area at time 0, and At is the correspondent scratch 
area at 24 h. The values shown are the means of three wells from three 
independent experiments. 
2.3.1.5 Statistical analysis 
Data are presented as means ±SD of at least three independent experiments. 
Comparisons are made by the Student’s t-test or by ANOVA when 
appropriate. Differences are considered statistically significant at P<0.05. 
Statistical analysis was carried out using StatView™ 5.0 software (SAS 
Institute, Cary, NC, USA). 
 
2.3.2	RESULTS	
2.3.2.1 Chemical characteristics of chitosan derivatives 
Data shown in Table 1 demonstrate that controlling the reaction temperature 
at 50 °C or 60 °C resulted in quaternary ammonium–chitosan derivatives 
very different from one another. Indeed, at 50 °C derivatives with lower 
quaternarization degrees and higher number of quaternary ammonium 
groups in substituted moieties were obtained, compared with polymers 
prepared at 60 °C. As can be deduced from relevant data in the table, 
significant fractions of unsubstituted glucosamine units were still present on 
the polymer chains. These were potentially available for covalent attachment 
of thiol groups via formation of amide bonds between the primary amino 
group of glucosamine and the carboxyl group of thioglycolic acid. The thiol 
content of N+-Ch(50°)-SH or N+-rCh(50°)-SH appears in Table 1 to be 
significantly higher of the respective values for N+-Ch(60°)-SH or N+-
rCh(60°)-SH. This is probably due to the higher number of glucosamine 
units available for thiolation in the respective parent N+-Ch and N+-rCh 
polymers. 
2.3.2.2 Cytotoxicity of low and high MW chitosan derivatives 
To determine the highest non-toxic concentrations of Ch and rCh derivatives 
fibroblasts were incubated for 24 h with 5, 10, 30, 50, 100 µg/ml of each 
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chitosan derivative. Dose-dependent cell viability indicated that in no case 
were significant cytotoxic effects observed at concentrations below 10 µg/ml 
(Fig. 1A and B). Actually, N+-rCh(50°) either thiolated or not, improved cell 
viability significantly compared with untreated cells (control) (Fig. 1B). In 
particular N+-rCh(50°) and N+-rCh(50°) SH were non-toxic up to 50 and 100 
µg/ml, respectively. For their part, both N+-rCh(50°) and N+-rCh(50°)-SH 
were found non-toxic up to 10 µg/ml. 
2.3.2.3 In vitro scratch wound healing assay 
In vitro scratch wound healing assay was carried out to observe the effects of 
Ch and rCh derivatives on the healing process. It can be observed in Fig. 2 
that, in the course of 24-h exposure to either N+-rCh(50°)-SH or N+-
rCh(60°)-SH, fibroblasts moved toward the opening to close the scratch 
wound by about 70% and significantly accelerated the wound healing 
process compared to the control. Finally, as can be observed in Fig. 3, of the 
rCh polymers only N+-rCh(50°)-SH showed a positive trend to wound 
healing. On the other hand, no significant effects were observed after 24 h of 
treatment with non-thiolated quaternary ammonium–chitosan conjugates or 
Ch·HCl or rCh·HCl, used as positive control. 
 
2.3.3	DISCUSSION		
Wound healing is a complex and dynamic process including inflammation, 
proliferation and remodeling, in which migration of fibroblasts plays an 
essential role in wound repair [171]. Chitosan, a derivative of chitin, which 
is one of the most abundantly found natural polymers, has numerous 
biomedical applications, in particular, chitosan has been used to promote 
wound healing [172,173,174]. In fact, chitosan is suitable for use in wound 
dressings, as not only it aids the healing process but also, it is biodegradable, 
biocompatible, non-toxic, bioadhesive, bioactive, non-antigenic, anti-
microbial and at the same time it exerts haemostatic effects [160,175]. 
However, the application of chitosan is often limited by its poor solubility in 
physiological media. To improve its water solubility it has been subjected to 
chemical modifications, including quaternization, carboxymethylation, etc. 
[176,177]. It has been demonstrated that chitosan induces fibroblast 
activation, cytokine production, giant cell migration and stimulation of type 
IV collagen synthesis by fibroblasts [178]. Shi et al. demonstrated that 
chitosans promote adequate granulation tissue formation, accompanied by 
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angiogenesis and regular deposition of thin collagen fibers [179]. Natural 
polymers such as chitosan, collagen and gelatine can successfully be used to 
fabricate wound dressings with desirable properties, since chitosan and 
similar substrates are the principal structural components of natural extra 
cellular matrix (ECM) [180]. Zhang et al. studied the effects of chitosan with 
different MWs and carboxymethyl chitosan on the structure and function of 
clotting-related proteins [173]. They observed that chitosan and fibrinogen 
can form a complex mainly by electrostatic attraction. In fact, the structure 
and conformation of fibrinogen are altered by chitosan and carboxymethyl 
chitosan [173]. The beneficial effects of chitosan and its derivatives depend 
on physicochemical properties, such as polymer MW and pH of solution, 
and chemical ones, such as type of moieties substituted on polymer chains. 
Wound healing properties of chitosans with different MWs and degrees of 
deacetylation were examined by Alsarra [181], who found that the strongest 
wound healing effect corresponded with high MW and deacetylation degree. 
To note that Seyfarth et al. [183] observed a direct influence of MW on 
antifungal activity of chitosans, i.e., a low antifungal activity was associated 
with a low MW. Also the deacetylation degree must have a role in the 
bioactivity of chitosan. Indeed, Howling et al. [161], who examined the 
effects of chitin and chitosan with different deacetylation degrees and 
similar MWs on the proliferation of human skin fibroblasts, reported that 
chitosans with relatively high deacetylation degree (89%) strongly 
stimulated fibroblast proliferation, while samples with lower deacetylation 
degree (37%) showed a lesser activity. It was on the basis of the above 
literature information that we used highly deacetylated chitosans for 
derivatization, namely, high-MW Ch, deacetylated by 82.5%; and low-MW 
rCh, deacetylated by 88.7%. Of the two, the former promoted the higher 
mean scratch closure rate, as appears from a comparison of relevant mean 
values in Figs. 2 and 3. Although this difference has a poor statistical 
significance it is in agreement with the reported influence of MW on 
chitosan bioactivity [180,181]. Derivatization of chitosans into quaternary 
ammonium–chitosan conjugates, although ineffective for wound healing, 
was necessary to grant the successively thiolated polymers a pH independent 
solubility, in turn necessary for the significant wound healing activity 
appearing in Fig. 2 for  N+-Ch(50°)-SH and N+-Ch(50°)-SH. Reportedly 
thiol groups are responsible for the enhanced bioactivity of thiolated poly- 
mers (thiomers). In fact, thiomers in combination with reduced glutathione 
were shown to improve the uptake of hydrophilic macromolecules from the 
GI tract [182]. Successively, Zambito et al. [39] reported that a chitosan 
derivative carrying thiol along with quaternary ammonium groups showed 
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an improved ability to enhance drug permeability across the rat intestinal 
mucosa compared with the non-thiolated polymer. Also, Zambito and Di 
Colo [18] found that a thiolated quaternary ammonium–chitosan derivative 
was more effective than the parent non-thiolated derivative in promoting the 
transcorneal absorption of dexamethasone. Our present data indicate that 
thiol groups substituted on the chains of high-MW quaternary ammonium–
chitosan conjugates also exert the function of aiding the wound healing 
process. Relevant data in Table 1 and Fig. 2 suggest that the significance of 
process acceleration is higher for the polymer with higher thiol content. On 
the other hand, the effects of the thiolated polymers appearing in Fig. 3 show 
poor significance, which can be ascribed, on the basis of the foregoing 
discussion, to the low MW of rCh compared to Ch. The higher efficacy of 
the higher-MW chitosan derivatives compared to the lower-MW ones is 
perhaps ascribable to an ability of the former to establish a co-operative 
interaction with ECM protein stronger than the latter, because the 
contributing active sites on the polymer chain are more numerous in the 
former instance. Nevertheless, the thiols present on the chains of the 
thiolated low-MW derivatives must still have some wound healing activity, 
since the rank order of the mean scratch closing rate produced by these 
polymers, appearing in Fig. 3, is the same as that seen in Fig. 2 for the 
significantly active thiolated high-MW derivatives. This order, indeed, 
corresponds with that of the thiol content listed in Table 1 for the high-MW 
and low-MW thiolated polymers. 
 
2.3.4	CONCLUSIONS		
The in vitro procedure used in this study has appeared suitably to 
discriminate between chitosan derivatives for their ability to promote wound 
healing by acting as a stimulus for fibroblast cell migration. In particular, 
results revealed that high-MW qua- ternary ammonium–chitosan conjugates 
bearing thiol groups on their chains are more effective in promoting cell 
activity and accelerating wound healing than the non-thiolated conjugates 
and the parent non-derivatized Ch. On the other hand, the effects of the cor 
responding thiolated quaternary ammonium–chitosan conjugates of low MW 
were statistically insignificant, although some wound healing activity of the 
thiols carried by these polymers could still be made out. 
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2.3.5	TABLES	AND	FIGURES		
Table 1. Chemical characteristics of chitosan and chitosan derivatives. 
Polymer DA (%) DS (%) n ThDS (%) 
Ch 17.5 − − − 
r-Ch 11.3 − − − 
N+-Ch(50°) − 21.1 4.1 − 
N+-Ch(60°) − 59.2 1.7 − 
N+-rCh(50°) − 26.4 3.8 − 
N+-rCh(60°) − 55.3 2.1 − 
N+-Ch(50°)-SH − − − 4.3 
N+-Ch(60°)-SH − − − 0.5 
N+-rCh(50°)-SH − − − 2.8 
N+-rCh(60°)-SH − − − 1.4 
 
DA, degree of acetylation; DS, degree of substitution; n, number of quaternary 
ammonium groups in substituted moieties; ThDS, degree of substitution by thiol-bearing 
groups. 
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Figure 1. Dose-dependent effect of different chitosan derivatives on cell 
viability. Human fibroblasts viability was assessed by WST-1 colorimetric 
assay (Abs 450 nm). Cells were treated with different concentration of high 
(A) and low (B) molecular weight chitosan derivatives (5-100 µg/mL) for 
24h. Data are representative of three independent experiments and are 
expressed as percentage of control (untreated cells). 
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Figure 2. Representative phase contrast micrographs of cells treated with 10 
µg/mL Ch (high MW) derivatives for 0 and 24h (5x magnification). Bar 
graphs represents the quantification of the effects of Ch derivatives on 
scratch wound healing. Bars represent the means ± SD of values obtained 
from three independent experiments. Wound closure rates are expressed as 
percentage of scratch closure after 24h compared to initial area. *P<0.05 and 
**P<0.1 vs control (untreated cells).  
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Figure 3.  Representative phase contrast micrographs of cells treated with 
10 µg/mL rCh (low MW) derivatives for 0 and 24 h (5x magnification). Bar 
graphs represent the quantification of the effects of rCh derivatives on 
scratch wound healing. Bars represent the means ± SD of values obtained 
from three independent experiments. Wound closure rates are expressed as 
percentage of scratch closure after 24h compared to initial area. Control 
consists in untreated cells.  
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2.4	DELIVERY	OF	NATURAL	POLYPHENOLS	BY	POLYMERIC	
NANOPARTICLES	IMPROVES	THE	RESISTENCE	OF	ENDOTHELIAL	
PROGENITOR	CELLS	TO	OXIDATIVE	STRESS		
Endothelial progenitor cells (EPCs) are bone marrow-derived cells that are 
mobilized to the peripheral circulation when vascular repair and 
neovascularization are required [187, 199]. Decreased availability of EPCs is 
one of several important mechanisms for the occurrence of vascular disease 
and dysfunction [200]. Moreover, EPC number is decreased in patients with 
coronary artery disease (CAD) and cerebrovascular disease [186, 187, 188]. 
The prevalence of CAD is low in populations that consume large amounts of 
red wine [201]. This low prevalence has been attributed to the antioxidant 
properties of red wine and increased nitric oxide (NO) bioavailability. 
[183,184]. However, alcohol consumption increases the incidence of 
cardiomyopathies, hypertension, and ictus. Moreover, alcohol appears to 
accelerate the deterioration process of antioxidants. Recent studies showed 
that the amount of red wine necessary to provide the organism with a level 
of phenolic compounds adequate to obtain a significant antioxidant effect is 
too high to avoid the deleterious consequences of alcohol [189]. For all these 
reasons, grape berries have recently been revaluated for their role as a source 
of polyphenolic compounds. Natural products are valuable sources of 
bioactive compounds, and have been considered the most successful 
discovery of modern medicine [202]. Cause of their low solubility, many 
phytochemicals are poorly absorbed by the human body, thus one of the 
most important and interesting function of formulating phytochemicals into 
dosage forms is to enhance their bioavailability by modifying their 
pharmacokinetics and biodistribution. 
Over the past few years, the synthesis, characterization, and bioactivity of 
polymeric epithelial permeability enhancers derived from chitosan (Ch) have 
been described [38, 196]. Ch has widely been used in pharmaceutical and 
medical areas, due to its favourable biological properties such as biodegrad- 
ability, biocompatibility, low toxicity, hemostatic, bacteriostatic, fungistatic, 
anticancer, and anticholesteremic properties [203]. Ch is obtained by 
alkaline deacetylation of the natural polysaccharide chitin, which is the 
polymer of beta-(1-4)-linked 2-acet-mido-2-deoxy-D-glucopiranose, 
obtained from the shells of marine crustaceans such as crabs and shrimps. 
Because of its chemical structure, Ch and its derivatives have been 
investigated to prepare controlled-release drug delivery systems, in 
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particular transmucosal formulations. In fact, in virtue of its mucoadhesive 
properties Ch can enhance transmucosal drug absorption and realize 
sustained drug release [204]. In a recent study Felice et al. [77] have shown 
that the natural antioxidant products extracted from Italian red grape skin 
and seeds (essentially polyphenols) can exert the same beneficial effects on 
EPCs as red wine. The study also showed the ability of a quaternary 
ammonium-chitosan conjugate to enhance the permeation of the above 
products across the excised rat intestine. These results pointed to potential 
advantages of an oral dosage formulation comprising the above dry extracts, 
as the active principles, and the Ch derivative, as the absorption enhancer. 
The aim of the present work has been to lay down the basis for the 
preparation of innovative therapeutic systems able to protect grape seed 
polyphenols from degradation and EPCs from the oxidative stress induced 
by H2O2. In particular, we were aimed at assessing the ability of polymeric 
nanoparticles to encapsulate different grape seed extracts, investigating the 
cellular uptake fate of the loaded nanoparticles and studying the impact of 
the loaded nanoparticles on EPC viability in comparison with the non-
encapsulated grape extracts. 
 
2.4.1	MATERIALS	AND	METHODS	
2.4.1.1 Plant material 
Sangiovese red grape seeds, either pre-veraison (p-GS) or ripe (r-GS), from 
Montecucco DOC area (Tuscany, Italy), were used for this study. Phenols 
were extracted according to Di Stefano and Cravero method [191] with some 
modifications. Immediately after sampling, both p-GS and r-GS from 10 
berries were freed from the attached mesocarp and quickly immersed in 25 
ml of an extraction buffer [191]. After 4 h extraction, each of p-GS and r-GS 
was homogenized and centrifuged 10 min at 3000g. The supernatant was 
analyzed for total polyphenols content by the Folin–Ciocalteu reagent 
(Sigma), as previously described [205]. The absorbance of the supernatant 
was measured at 750 nm (Perkin Elmer, Lambda 25). 
The antioxidant concentration was expressed as [µg catechin]/[l supernatant] 
with reference to a (+)-catechin standard calibration curve. Afterward, each 
of the p-GS and r-GS supernatant was lyophilized (VirTis adVantage, 
thermal treatment step: -35 °C for 360 min; drying cycle steps: -35 °C for 
240 min; -25 °C for 360 min; +10 °C for 300 min; +25 °C for 120 min) to 
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obtain the dry GS extracts (p-GSE and r-GSE, respectively). 
2.4.1.2 Determination of in vitro antioxidant capacity and 
resveratrol content of grape seed extracts 
The total antioxidant potential of each of p-GSE and r-GSE was determined 
using the ferric-reducing antioxidant power (FRAP) assay [206]. This is 
based on the reduction of Fe+3-TPTZ to a blue-coloured Fe+2-TPTZ. The 
absorbance was read at 593nm (Perkin Elmer, Lambda 25 
spectrophotometer). The FRAP value of sample, expressed as mg of Fe+2 per 
ml, was determined from a standard curve built up using ferrous sulphate. 
The quantification of trans-resveratrol (Resv) was performed as previously 
described [207] with minor modifications. Briefly, p-GSE and r-GSE 
samples of known concentration in phosphate buffer pH 7.4, 0.13 M, were 
analysed by HPLC (UV detection at 310 nm, Phenomenex column 250 × 4.6 
mm, C18, 5 m, mobile phase water/acetonitrile/acetic acid (70:29.9:0.1), 
flow rate 0.8 ml/min, injection volume 20 µl). To quantify the Resv content 
in samples reference was made to a calibration curve constructed with 
standard solutions of Resv (Sigma) in the 0.1–1.5 µg/ml concentration range 
in 12% aqueous ethanol. 
2.4.1.3 EPCs isolation and culture 
EPCs were isolated from total peripheral blood mononuclear cells (PBMCs) 
after 3 days of culture in a selective medium, as previously described [208]. 
Briefly, PBMCs from a healthy human donor were isolated by density 
gradient centrifugation on Lymphoprep (Nycomed, Oslo, Norway; density = 
1.077 g/ml) at 400 g for 30 min at room temperature, according to the manu- 
facturer’s protocol. After centrifugation, the interface cells were carefully 
removed and transferred to a new conical tube. After washing in PBS, 
isolated PBMCs (1 × 106 cells/cm2) were plated on 96-well plates (Greiner 
Bio One, Frickenhausen, Germany) coated with fibronectin and maintained 
in endothelial basal medium (EBM-2, Cambrex, Walkersville, MD) 
supplemented with EGM-2-MV-Single Quots containing human endothelial 
growth factor, hydrocortisone, insulin-like growth factor, fibroblast growth 
factor, vascular endothelial grow factor (VEGF), antibiotics, and 5% fetal 
bovine serum (FBS, Cambrex). Cells were cultured at 37 °C with 5% CO2 in 
a humidified atmosphere. After 4 days of culture, non-adherent cells were 
removed by washing with PBS (1×), and adherent cells were exposed to the 
different experimental conditions. 
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2.4.1.4 Preparation and characterization of GSE loaded 
nanoparticles based on thiolated quaternary ammonium-chitosan 
derivatives 
Reduced-molecular weight chitosan (rCh) and hyaluronic acid (rHA) were 
prepared by Zambito et al. [115]. Two structurally different thiolated 
quaternary ammonium-chitosan conjugates, coded N+-rCh(60°)-SH and N+-
rCh(50°)-SH, respectively, were synthesized from rCh, and FITC-labelled, 
by Zambito et al. [115]. To prepare p-GSE or r-GSE loaded nanoparticles 
(NP) based on N+-rCh(60°)-SH (NP1) a 400 µl PBS volume containing 
0.022 mg/ ml rHA and 2.5 mg/ml p- or r-GSE was added portionwise (50 µl) 
to 5 mL of 2 mg/ml rCh derivative solution in PBS under stirring. A similar 
procedure was followed to prepare GSE loaded NP based on N+-rCh(50°)-
SH (NP2). In this case 50 µl aliquots of 600 µl PBS containing 0.011 mg/ml 
rHA and 1.67 mg/ml p- or r-GSE were successively added to stirred 5 ml of 
2 mg/ml rCh derivative solution in PBS. Following preparation, each NP 
dispersion was centrifuged at 12,500 rpm for 1 h and the supernatant 
analysed by the Folin–Ciocalteu reagent for total content of antioxidant 
material (AOMsup), as described previously [77], in order to calculate the NP 
entrapment efficiency (EE), according to the following expression: 
EE= (GSEtot−AOMsup)/GSEtot 
where GSEtot represents the total GSE mass used for each NP preparation. 
The absorbance from the Folin–Ciocalteu reaction was read at 750 nm with 
reference to a spectrophotometer calibration made with GSE standard 
solutions. Blank NP1 and NP2 were prepared, according to a previous report 
[115], centrifuged, and the respective supernatants analyzed as described 
above. Any interference with the analysis of the GSE-loaded NP1 and NP2 
could be ruled out. The size and zeta-potential of GSE-loaded NP were 
measured (Nano Z690 Malvern). The physical stability of GSE-NP 
dispersions was fair, in analogy with that of the blank NP, evaluated 
previously [115]. 
2.4.1.5 Cell treatment 
After 4 days of culture, adherent EPCs were pre-incubated for 3 h with p-
GSE or r-GSE diluted in a serum-free medium to different concentrations of 
µg catechin/l (5 µg/ml, 50 µg/ml, 150 µg/ml). Also, EPCs were pre-
incubated for 3 h or 12 h with GSE loaded NP1 or NP2, then, after the same 
GSE dilution as the above, they were treated with 1 mM H2O2 for 1 h. At the 
end of the treatment, cells were washed twice with PBS and analyzed for 
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viability and production of reactive oxygen species (ROS). The 
concentration of either p-GSE or r-GSE used to load the nanoparticles was 
below the level of toxicity, as shown by the WST-1 assay. 
2.4.1.6 Cell viability 
Cell viability was tested by the WST-1 assay, based on the cleavage of 
tetrazolium salt (WST-1, 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-
tetrazolium]-1,3-benzene disulfonate, Roche Applied Science, Mannheim, 
Germany) by mitochondrial dehydrogenases, present in viable cells. Briefly, 
at the end of the treatment EPCs were incubated with tetrazolium salt (10 
µl/well) for 4 h at 37 °C, 5% CO2. Then, the formazan dye formed was 
quantified by measuring the optical density at 450 nm, with a multiplate 
reader (Titertek). The absorbance directly correlated to the number of 
metabolically active cells. Viability was expressed as percent of viable cells, 
calculated from the ratio of absorbance after treatment to mean absorbance 
for the untreated control. 
2.4.1.7 ROS production 
ROS production was evaluated by ROS-sensitive fluorescent probe 5-(and-
6)-chloromethyl-20,70-dichloro-di-hydro-fluorescein diacetate, acetyl ester 
(CM-H2DCFDA) (Invitrogen). Briefly, after treatment, EPCs were washed 
with PBS and incubated with CMH2DCFDA (10 µM/well) for 30min at 
room temperature in the dark. Then cells were washed twice with fresh PBS, 
and ROS production was detected in EPCs by measuring the increase in 
fluorescence by microplate reader. Fluorescence was measured by excitation 
at 488 nm and emission at 510 nm. 
2.4.1.8 Intracellular uptake of nanoparticles 
EPCs were incubated for 3 or 12 h in a serum-free medium with either p-
GSE or r-GSE loaded NP1 or NP2 dispersion prepared from FITC-labelled 
chitosan derivative. Intracellular uptake was observed under a fluorescence 
microscope (Carl Zeiss, Germany) at 10× magnification, after nuclear 
labelling of EPCs with Hoechst 33258 (1:1000) (Sigma–Aldrich). 
2.4.1.9 Statistical analysis 
Data represent means ± SD of at least three independent experiments. The 
difference among groups was evaluated by a one- or two-factor ANOVA by 
two independent investigators in a blinded fashion. Post hoc analysis was 
performed by Student–Newman– Keuls testing. Statistical significance was 
accepted at P < 0.05 or less. 
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2.4.2	RESULTS	
2.4.2.1 Physical characteristics of GSE loaded NP and GSE 
analysis 
The physical characteristics of GSE loaded NP are listed in Table 1. Neither 
the mean particle size nor the polydispersity index appears to significantly 
depend on the type of either the rCh derivative from which the NP were 
prepared or the GSE with which they were loaded. On the other hand the 
zeta potential of NP1 was significantly, although slightly, higher than that of 
NP2. p-GSE contained a high content of total polyphenols (2.346 g 
catechin/l) compared to r-GSE (1.096 g catechin/l) (Fig. 1A). In addition, at 
the same total polyphenols concentration, p-GSE also showed a stronger 
antioxidant capacity than r-GSE (0.257mg Fe+2/ml vs 0.220 mg Fe+2/ml) 
(Fig. 1B). The Resv content was higher in r-GSE (220 nM) than in p-GSE 
(26 nM). 
2.4.2.2 Effect of p-GSE or r-GSE on EPCs viability 
Cell viability was evaluated by WST-1 colorimetric assay. To determine 
non-toxic concentration of r-GSE and p-GSE, EPCs were incubated for 3 h 
in the presence of different concentrations of extracts (2–150 µg/ml of total 
polyphenols). Dose-dependent EPC viability indicated that no significant 
cytotoxic effects were observed at GSE concentrations below 5 µg/ml of 
total polyphenols. On the other hand, a significant decrease of cell viability 
(75%) was observed at p-GSE concentrations equivalent to 5 µg/ml of total 
polyphenols and at r-GSE concentrations equivalent to 25 µg/ml of total 
polyphenols (Fig. 2). 
2.4.2.3 Intracellular uptake of NP loaded with GSE 
The uptake of nanoparticles by EPCs upon incubation with GSE loaded 
FITC-labelled NP1 or NP2 for different times (3 or 12 h) is shown by the 
images in Fig. 3. After 3 h both NP types were partially internalized by cells, 
GSE-NP1 being seemingly taken up to a higher extent than GSE-NP2. This 
difference can safely be correlated with the stronger positive surface charge 
of the former, resulting from the zeta-potential measurements [115]. 
However, 12 h of incubation shows a progress of the internalization process 
that still appears more advanced with the GSE-NP1 than the GSE-NP2 
nanoparticles. 
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2.4.2.4 Antioxidant activity of free GSE and nanoencapsulated 
GSE 
Fig. 4 shows p- and r-GSE effect on ROS accumulation in EPCs as 
determined by CM-H2DCFDA, a cell-permeable indicator for these 
compounds. Both p- and r-GSE did not induce ROS production after 3 h or 
12 h of incubation (Fig. 4A and B, respectively). Moreover, 3 h of pre-
incubation with p-GSE prevented ROS production induced by 1 mM H2O2 
(p < 0.01 vs H2O2), a prevention that was not observed after 12 h of pre-
incubation. Fig. 5 shows ROS accumulation in EPCs incubated with p- or r-
GSE encapsulated in NP1 (A) or NP2 (B). As show in Fig. 5A, either 3 h or 
12 h incubation with p- or r-GSE encapsulated in NP1 prevented ROS 
accumulation induced by H2O2 treatment. When EPCs were incubated with 
r-GSE encapsulated in NP2, 3 h but not 12 h of pre-incubation, prevented 
ROS accumulation induced by H2O2. On the other hand, p-GSE 
encapsulated in NP2 showed a protective effect both after 3 h and 12 h of 
pre-incubation. 
2.4.2.5 Protective effect from oxidative stress of free GSE and 
nanoencapsulated GSE 
Treatment of EPCs with H2O2 reduces viable cell number (209). 
Accordingly, when EPCs were incubated with 1 mM H2O2 for 1 h the viable 
cell number significantly decreased compared to untreated control cells (P < 
0.05). As shown in Fig. 6A, 3 h pre-incubation with p-GSE (2 µg/ml of total 
polyphenols), prevented the H2O2 induced reduction of viable cell number (P 
< 0.001 vs H2O2). On the other hand, 2 µg/ml of r-GSE did not preserve 
EPC viability from the effect of H2O2. After 12 h of pre- incubation only p-
GSE preserved EPC viability significantly, nevertheless a comparison 
between relevant data in Fig. 6B shows a trend of r-GSE to enhance the 
protection of cell viability compared to 3 h pre-treatment. p-GSE or r-GSE, 
at a concentration corresponding to 2 µg/ml catechin, was encapsulated in 
either NP1 or NP2 to evaluate the protective effect of NP on EPCs. Cells 
were pre-incubated for 3 h and 12 h with either p- or r-GSE loaded NP1 
(Fig. 6C) and either p- or r-GSE loaded NP2 (Fig. 6D). As shown in Fig. 6C, 
3 h pre-incubation with p-GSE-NP1 prevented cell viability reduction 
induced by 1 mM H2O2. Moreover, r-GSE-NP1 shows a positive trend in the 
protection of cell viability. After 12 h pre-incubation, both p- GSE-NP1 and 
r-GSE-NP1 protected cells from oxidative damage (P < 0.001 vs H2O2). Fig. 
6D, shows GSE-NP2 effects on EPC viability. Unlike p-GSE- NP2, r-GSE-
NP2 did not protect cell viability from oxidative stress after 3 h or 12 h of 
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pre-incubation. 
 
2.4.3	DISCUSSION		
Numerous studies show the protective effect of grape seed extracts on 
endothelial injury [210, 77]. GSE-rich diets have been associated with a 
reduced risk of chronic cardiovascular diseases [211]. Our results show that 
p-GSE are more effective than r-GSE to protect EPC from oxidative stress. 
These results can be due to the fact that grape seed polyphenols undergo 
significant changes during grape maturation [212]. In fact, the seed extracts 
from grapes collected at pre-veraison display higher contents of the total 
polyphenolic compounds compared to the seed extracts from grapes 
collected at reap. At the same polyphenolic concentration, p-GSE have 
showed an higher antioxidant activity, that can explain their protective effect 
on the cells. In the present report we prepared a biodegradable nanoparticle 
formulation of polyphenols extracted from grape seeds and tested its effects 
on the viability of EPCs subjected to oxidative stress. GSE loaded NP1 
showed in vitro much higher cellular uptake than GSE loaded NP2. In 
particular, NP1 were seemingly taken up to a higher extent than NP2. This 
difference can safely be correlated with the stronger positive surface charge 
of the former, resulting from the zeta potential measurements, which allows 
cells to respond positively to the protective effect mediated by p-GSE and r-
GSE. Moreover, NP1 improves the protective effect of r-GSE after showed a 
higher antioxidant activity that can explain their protective effect of r-GSE 
after 2 h compared to NP2, probably by protecting the extract from 
degradation. Free r-GSE did not preserve EPC viability from the effect of 
H2O2. However, 12 h of incubation shows a trend of r-GSE to enhance the 
protection of cell viability compared to 3 h pre-treatment. On the contrary, r-
GSE-NP2 did not protect cell viability from oxidative stress after 3 h or 12 h 
of pre-incubation. These results may be due to the lower cellular uptake of 
NP2 that prevent the protective effect of r-GSE. Oxygen-free radical-
induced oxidative stress is expected to cause membrane lipid peroxidation, 
membrane protein damage, altered antioxidant system, DNA mutation, 
altered gene expression, and apoptosis, thereby leading to cardiovascular 
disease, atherosclerosis and other neurodegenerative diseases [213]. If 
internalized by EPCs, nanoparticles might protect cells from oxidative 
stresses by virtue of the antioxidant action of their thiols and encapsulated 
extracts made of polyphenols. In order to verify this hypothesis, the 
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influence of EPC pre-treatment with GSE loaded nanoparticles on the effect 
of cell incubation with H2O2 was investigated. EPCs were pre-treated for 3 h 
and 12 h with either GSE loaded nanoparticle type, and then incubated with 
1 mM H2O2 for 1 h. Interestingly, the results showed that ROS accumulation 
in EPCs, measured by fluorescent CM-H2DCFDA, was decreased by a pre-
treatment with GSE loaded NP1 for either 3 h or 12 h, whereas with NP2 no 
significant decrease was observed after 12 h of pre-treatment. Considering 
that NP1 are the nanoparticle type with more aptitude to be internalized, as 
seen in Fig. 3, the above findings can be taken as a support of the initial 
hypothesis. The nanoparticles showed an aptitude to be internalized by EPCs 
directly related to the intensity of their surface charge. In virtue of the 
antioxidant function of their thiols, the nanoparticles more apt to be 
internalized can significantly improve cell viability and resistance to 
oxidation by hydrogen peroxide. This beneficial effect is strengthened by 
biocompatible antioxidant materials loaded into nanoparticles. 
 
2.4.4	CONCLUSION		
The present findings lead to the conclusion that the lyophilized NP could be 
a manageable formulation for oral application, seeing that it might be filled 
into gastro-resistant capsules and could regenerate the nanosystem in 
buffered conditions upon contact with the physiologic fluids of the GI tract, 
to improve polyphenols adsorption and antioxidant effects. The effectiveness 
of such a formulation will be the object of a further study. 
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2.4.5	TABLES	AND	FIGURES		
Table 1. Physical characteristics of GSE loaded NP. The EE is in all cases 
93±5%.  
p-GSE: pre-veraison grape seeds extract; r-GSE: ripe grape seeds extract; NP1: N+-rCh 
(60°)-SH/rHA nanoparticles; NP2: N+-rCh (50°)-SH/rHA nanoparticles. 
 
Figure 1. Grape seeds extract characterization. Total polyphenols content 
(A) and antioxidant capacity (B) of p-GSE and r-GSE were measured with 
Folin-Ciocalteu’s phenol reagent method and FRAP assay, respectively. 
Data are expressed as means ± SD and are representative of five 
determinations in duplicate. 
 
  
Particle type Particle size±SD (nm) Polydispersity index Zeta potential (mV) 
p-GSE loaded NP1 325±38 0.415±0.016 +11.35±1.1 
p-GSE loaded NP2 311±40 0.448±0.031 +8.3±1.0 
r-GSE loaded NP1 333±41 0.433±0.020 +10.26±1.3 
r-GSE loaded NP2 311±40 0.449±0.033 +7.8±1.4 
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Figure 2. Dose-dependent cell viability. EPCs were cultured for 3h in the 
presence of p-GSE or r-GSE (from 2 µg/mL up to 150 µg/mL of total 
polyphenols). Cell viability was determined by WST-1 colorimetric assay 
and expressed as % viability compared to control (untreated cells).  Data are 
representative of three separate experiments in triplicate. 
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Figure 3. Cellular uptake of encapsulated grape seeds extract. Images from a 
fluorescence microscope, showing uptake of grape seeds extract (GSE) 
loaded FITC-labelled NP1 or NP2 by EPCs after 3 or 1 h of incubation, 
arrows indicate the outside fluorescence. The histogram shows the 
percentage of FITC-labelled NP optical density outside the cells. 
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Figure 4. Antioxidant activity of free grape seeds extracts. ROS production 
in EPCs treated with p- or r-GSE (2 µg/mL of total polyphenols) for 3 h (A) 
or 12 h (B) and 1 mM H2O2 for 1 h. Data are expressed as % ROS 
production compared to cell treated with H2O2 and are representative of three 
experiments in triplicate. *P < 0.05 vs ctr; § P < 0.01 vs H2O2. 
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Figure 5. Antioxidant activity of encapsulated grape seeds extracts. ROS 
accumulation in EPCs treated with p- or r-GSE encapsulated in NP1 (A) and 
NP2 (B) and treated with 1 mM H2O2 for 1 h. Data are expressed as % ROS 
production compared to cell treated with H2O2 and are representative of three 
experiments in triplicate. *P < 0.05 vs ctr; § P < 0.01 vs H2O2. 
	
	
A 
B 
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2.5	NANOPARTICLES	BASED	ON	QUATERNARY	AMMONIUM-
CHITOSAN	CONJUGATE:	A	VEHICLE	FOR	ORAL	ADMINISTRATION	
OF	ANTIOXIDANTS	CONTAINED	IN	RED	GRAPES		
It has been reported that the incidence of coronary artery disease is 
comparatively low with populations that consume large amounts of red wine 
[74] thanks to the antioxidant properties of polyphenols, contained in red 
wine, and increased nitric oxide bioavailability [183, 184]. These factors 
exert their beneficial effects on endothelial progenitor cells (EPC), i. e., bone 
marrow-derived cells that are mobilized to the peripheral circulation when 
vascular repair and neovascularization are required [185]. In fact, the EPC 
number is decreased in patients with coronary artery disease and 
cerebrovascular disease [186,187,188]. Unfortunately the amount of red 
wine needed to provide a level of phenolic compounds in the organism 
adequate to produce a significant antioxidant effect is too high to allow one 
to disregard the harmful consequences of alcohol [189], such as increased 
incidence of cardiomyopathies, hypertension and ictus. In a recent study it 
was shown that the antioxidant products extracted from Italian red grape 
skin and seeds (essentially polyphenols) can exert the same beneficial effects 
on EPC as red wine, in the absence of alcohol [77]. Aiming at designing an 
adequate pharmaceutical system for administration of red grape seed extracts 
(GSE), nanoparticle dispersions were prepared by ionotropic gelation of 
thiolated quaternary ammonium-chitosan conjugates with hyaluronic acid 
[190]. To control the particle size to the nano-scale the MWs of polymers 
were reduced by controlled de-polymerization. GSE could be entrapped into 
the nanoparticle system up to around 90%. Uptake of nanoparticles, 
prepared from FITC-labelled chitosan derivative, into EPC was observed 
under a fluorescence microscope. Internalisation of GSE-loaded 
nanoparticles by EPC resulted in cell protection from oxidative stress [190]. 
For storage the nanoparticle dispersion was lyophilised. Since the dispersion 
could be regenerated from the lyophilised product by mild agitation in water, 
it was felt that the lyophilised GSE-loaded nanoparticles could make a sound 
pharmaceutical system for oral administration of natural antioxidants [190]. 
In fact, free, non-encapsulated GSE are barely bioavailable due to poor 
absorption and rapid oxidation upon contact with physiological fluids. 
Nevertheless, the following requirements should also be met by the 
nanoparticle dispersion for being accepted as an effective vehicle for GSE 
oral administration: (1) the particles should be able to penetrate across the 
intestinal epithelium into the bloodstream still preserving their 
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supramolecular aggregation state and size; (2) the particles should retain a 
significant load of antioxidant material for at least the time needed for their 
intestinal absorption and uptake by the target EPC. Demonstrating these 
properties of GSE-loaded nanoparticulate systems obtained by ionotropic 
crosslinking of either quaternary ammonium-chitosan conjugate, or its 
thiolated derivative, with hyaluronan has been the purpose of the present 
work. Point (1) was addressed by bringing the FITC-labelled nanoparticle 
dispersion into contact with the mucosal side of excised rat intestine in an 
Ussing type chamber for a measured time, after which the fluorescence of 
acceptor medium was measured, and gut slices were cut and observed under 
a fluorescence microscope. Concerning point (2), GSE release from the 
nanoparticles was studied by lyophilizing the nanoparticle dispersion 
immediately after preparation, re-generating the dispersion from the 
lyophilised product in stirred water at time zero, withdrawing aliquots of 
dispersion at measured intervals, centrifuging them, and analyzing each 
supernatant for its GSE content by the Folin-Ciocalteu reagent. 
 
 
2.5.1 MATERIALS AND METHODS 
 
2.5.1.1 Materials  
The GSE used in this study was taken from the batch obtained previously 
[190] from Sangiovese pre-veraison red grape seeds, from Montecucco DOC 
area (Tuscany, Italy), following the extraction procedure described by Di 
Stefano and Cravero [191]. Reduced–MW chitosan (rCh, viscometric MW 
32 kDa) and hyaluronic acid (rHA, viscometric MW 470 kDa) were 
prepared by Zambito et al. [115]. Of the quaternary ammonium-chitosan 
conjugates synthesised from rCh (QA-rCh50 and QA-rCh60) and thiolated 
(QA-rCh50-SH and QA-rCh60-SH) by Zambito et al. [115], the non-
thiolated QA-rCh60, and the thiolated QA-rCh60-SH were used for the 
present study. Both were FITC-labelled according to a previously described 
procedure [192, 193, 108]. All aqueous solutions/dispersions were prepared 
with freshly distilled water. 
 
2.5.1.2 Identification of GSE constituents 
The GSE constituents were separated and identified by HPLC-PDA-ESI-
MS/MS analysis using Surveyor LC pump, a Surveyor autosampler, coupled 
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with a Surveyor PDA detector, and a LCQ Advantage ion trap mass 
spectrometer (Thermo Finnigan, San Jose, CA, USA) equipped with 
Xcalibur 3.1 software. Analyses were performed using a Synergi 4 µ Fusion-
RP 80 A, 150x4.60 mm column (Phenomenex, Bologna, IT). The eluent was 
a mixture of 0.1% acetonitrile solution of CH3COOH (solvent A) and a 0.1% 
aqueous solution of CH3COOH (solvent B). The solvent gradient was as 
follows: 0-30 min, 5-30% A, 30-31 min, 30-70% A, 31-36 min, 70-100% A. 
Elution was performed at a flow rate of 0.8 mL/min with a splitting system 
of 2:8 to MS detector (160 mL/min) and PDA detector (640 mL/min), 
respectively. The volume of the injected acetonitrile GSE solution (1 
mg/mL) was 10 mL. Analyses were carried out with an ESI interface in the 
negative mode. The ionization conditions were optimized, and the 
parameters were as follows: capillary temperature, 320 °C; capillary voltage, 
-10.00 V; tube lens offset, -35.00 V; sheath gas flow rate, 40.00 arbitrary 
units; auxiliary gas flow rate, 15.00 arbitrary units; spray voltage, 4.50 kV; 
scan range of m/z 150.00-2000. PDA data were recorded over the 210-600 
nm range with preferential channel 280 nm as the detection wavelength.  
 
2.5.1.3 Quantitative determination of whole antioxidant 
competence of GSE 
The antioxidant competence of GSE constituents as a whole was correlated 
with concentration by reacting standards, of known GSE concentrations in 
phosphate buffer pH 7.4 (PB) 0.13 M (isosmotic), with the Folin-Ciocalteu 
reagent (Sigma), and measuring the resulting absorbance at 750 nm, as 
previously described [77]. Samples and standards were stabilized for at least 
5 h by adding 0.05 mg/ml N-acetylcysteine (NAC). A linear absorbance-
concentration correlation was found (r2=0.996; n=4) which allowed 
determination of unknown GSE sample concentration by the following 
equation: 
Concentration = (Absorbance – 0.022)/0.0978 
 
2.5.1.4 Preparation of nanoparticles 
To prepare GSE-loaded nanoparticles (NP) based on QA-rCh60, QA-rCh60-
SH, or these polymers labelled with FITC, a 400 µl volume of PB, 0.13 M 
(isosmotic) containing 0.022 mg/ml rHA and 3.1 mg/ml GSE was added 
portionwise (100 µl) to 5 ml of 2 mg/ml rCh derivative solution in PB of 
different strength (0.13 M (isosmotic), 0.026 M, 0.013 M or 0.007 M), under 
stirring. The resulting particles were analysed for size by light scattering 
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(Nano Z690 Malvern). Blank NP were prepared by the same procedure, 
except that the rHA solution contained no GSE. Following preparation, each 
GSE loaded and blank NP dispersion was centrifuged (19,500 rpm, 1 h) and 
the supernatant analysed by the Folin–Ciocalteu reagent for total content of 
antioxidant material, as described in section 2.5.1.3. To obtain the GSE 
amount in the supernatant (GSEsup) the absorbance for the blank NP was 
subtracted from that for the GSE loaded NP. The NP entrapment efficiency 
(EE) was calculated by the following equation: 
 
EE = (GSEtot - GSEsup)/GSEtot 
 
where GSEtot represents the total GSE mass used for the NP preparation. 
To obtain stable systems the GSE-loaded NP dispersions were lyophilised 
(VirTis adVantage, thermal treatment step: -35 °C for 180 min; drying cycle 
steps: -30 °C for 360 min; -10 °C for 360 min; +10 °C for 240 min; +25 °C 
for 180 min). The NP dispersions could be regenerated from the respective 
lyophilised products by adding water under gentle stirring. In each case a 
water volume was added apt to generate an isosmotic dispersion, namely, 5, 
1, 0.5, 0.3 ml water was added to lyophilised products obtained from NP 
dispersions in 0.13, 0.026, 0.013, 0.007 M PB, respectively. By this 
procedure isosmotic pH 7.4 dispersions of different NP concentrations could 
be obtained.  
 
2.5.1.5 Study of lyophilised GSE-loaded NP ability to retain 
antioxidant material after regeneration 
Three lyophilised QA-rCh60 or QA-rCh60-SH-based GSE-loaded NP 
preparations in PB 0.026 M were pooled and regenerated with 3 ml water 
containing 0.05 mg/ml NAC for GSE stabilization, as described in section 
2.5.1.3. The regenerated dispersions were stirred at 37 °C. At times 0, 1 and 
4 h 1 ml of each regenerated NP dispersion was withdrawn, centrifuged 
(19,500 rpm, 1 h), and the supernatant analysed for GSEsup as described in 
section 2.5.1.4, with reference to blank NP subjected to the same procedure. 
 
2.5.1.6 Study of NP penetration across intestinal barrier 
The intestinal mucosa used for these studies was excised from non-fasting 
male Winstar rats weighing 250–300 g. This was done under veterinary 
supervision, and the protocol was approved by the ethical scientific 
committee of the University of Pisa. After sacrificing the rats, the first 20 cm 
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of jejunum were immediately removed. The excised intestine was cut into 
strips of 1.5 cm, rinsed free of luminal contents and mounted in Ussing type 
chambers (0.78 cm2 exposed surface area) without stripping off the 
underlying muscle layer. One and 3 ml of PB pH 7.4, 0.13 M (isosmotic) 
were added to the mucosal (donor) and serosal (acceptor) compartment, 
respectively, of the permeation cell. In order to ensure oxygenation and 
agitation, a mixture of 95% O2 and 5% CO2 was bubbled through each 
compartment. The Ussing chamber was then placed in a thermostatic water 
bath at 37°C. After 20 min equilibration the medium in the donor 
compartment was replaced by 1 ml of pre-equilibrated FITC-labelled GSE-
loaded QA-rCh60- or QA-rCh60-SH-based NP dispersion in PB pH 7.4, 
0.13 M, or 2 mg/ml sodium fluorescein (NaFlu) in PB pH 7.4, 0.13 M. After 
1-h incubation the concentration of the fluorescent material in the receiving 
phase was measured fluorometrically (excitation, 485 nm; emission, 530 
nm) with reference to the relative calibration curve. To observe the 
incubated intestinal tissue under an optical microscope the following 
procedure was implemented. After 1h incubation in Ussing chamber, strips 
of intestinal tissue were ﬁxed in 4% phosphate-buffered paraformaldehyde 
overnight at 4°C. Samples were then dehydrated through a graded series of 
ethanol, cleared with xylene, and embedded in parafﬁn according to standard 
histological techniques. Sections, 8 µm-thick, were cut across the long axis 
of the gut lumen to obtain sections of whole thickness intestinal wall, from 
mucosal to serosal layer. Slides were then deparaffined, rehydrated and 
processed for routine haematoxylin-eosin staining, or mounted with 
glycerol/ deyonized H2O (2:1) for fluorescence examination. Sections were 
observed on an Olympus BX60 light-fluorescence microscope. 
Representative photomicrographs were captured by Nikon DS-Fi1 digital 
camera. For each sample, at least 3 serial sections were examined. 
 
 
2.5.2 RESULTS AND DISCUSSION 
 
2.5.2.1 GSE constituents 
The GSE acetonitrile solution was analyzed by means of HPLC-PDA-ESI-
MS/MS. The resulting chromatograms, showing nine main peaks (1-9), are 
depicted in Fig. 1. The results revealed the presence in the GSE preparation 
of mainly secondary metabolites belonging to the proanthocyanidin class, as 
indicated by absorbance at 280 nm (Table 1); nine of them were identified 
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by comparison of their HPLC retention times, elution orders, ESI-MS 
spectrometric data, and photodiode array PDA/UV-vis with those reported in 
the literature and with available reference compounds [16-18]. Full mass 
spectra of peaks 1-9 showed deprotonated molecules [M-H]- at m/z 865, 577, 
289, 865, 577, 289, 865, 729, and 441, respectively. The LC-MS base peak 
chromatograms, all the chromatographic, spectroscopic, and spectrometric 
data of the detected compounds are reported in Table 1.  
2.5.2.2 NP characteristics 
The size and EE characteristics of GSE-loaded NP, based on an either 
thiolated or non-thiolated quaternary ammonium-chitosan conjugate, 
immediately after their preparation in PB of different molarity are listed in 
Table 2. For whichever NP type the mean particle size appears to be 
independent of PB molarity in the 0.007-0.13 M range. The size was in all 
cases small enough to allow anticipating particle aptitude for internalisation 
by cells. The polydispersity index values seen in the table, on the average 
lower for the thiolated than the non-thiolated polymer, point to NP 
dispersions more uniform in size in the former than the latter instance. The 
table shows EE values around 80% for dispersion PB molarities in the range 
0.007-0.026 whereas, for the higher molarity of 0.13 the EE values appear to 
be significantly lower whichever the constituent polymer of NP, possibly 
due to the higher ionic strength of the medium. 
To stabilize the NP systems the freshly prepared dispersions in PB were 
lyophilised, with the view of readily regenerating the dispersions from the 
lyophilised products when needed. Each lyophilised NP dispersion was 
regenerated with a water volume depending on the PB content in the 
lyophilised product, such as to obtain an NP dispersion in an isosmotic 
medium. Since the lyophilised products contained amply varying PB mole 
numbers, each dispersion was regenerated with an amply varying water 
volume. On the other hand the polymer content was the same in each 
lyophilised product, therefore the regenerated dispersions contained amply 
different polymer concentrations, as can be seen in Table 3. It appears from 
a comparison of corresponding data in Tables 2 and 3 concerning particle 
size that lyophilisation/regeneration in all cases caused a significant size 
increase compared to the freshly prepared NP dispersions. Nevertheless in 
the case of NP based on QA-rCh60 or QA-rCh60-SH, dispersed in PB 0.026 
M, regenerated with 1 ml water (polymer concentration, 10 mg/ml) such an 
increase was not so marked as to make the particles grow beyond the upper 
size limit reported by Norris et al. for the particles able to cross the intestinal 
barrier (500 nm) [194].  
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2.5.2.3 Ability of lyophilised GSE-loaded NP to retain 
antioxidant material after regeneration 
The results of the studies of GSE release from lyophilised/regenerated NP 
dispersions, represented in Fig. 2, show that with either NP type around 80% 
of the GSE present in the dried product was dissociated from the 
nanoparticle matrix ever since regeneration of the dispersion (time 0). 
Considering that the EE determined for the just-prepared NP was about 
80%, as shown in Table 2, it must be deduced that the lyophilisation process 
caused a significant dissociation of GSE from either the thiolated or non-
thiolated NP. Nevertheless, a fraction of 15-20% of the GSE contained in the 
lyophilised product was steadily retained by either NP type for at least 4 h, a 
term presumably sufficient for NP penetration across the intestinal 
epithelium into the bloodstream and internalisation by EPC along with their 
load of antioxidant material.  
 
2.5.2.4 NP penetration across intestinal barrier 
The results of these studies are presented in Fig. 3 as fluorescent mass 
fraction penetrated across the excised rat intestinal wall in one hour of 
incubation.  
As can be seen, a substantial fraction, in the 75-80% range, of total 
fluorescent mass penetrated into the acceptor medium from GSE-loaded NP 
based on either FITC-QA-rCh60 or FITC-QA-rCh60-SH. On the other hand, 
the mass fraction permeated from the NaFlu solution was as small as 2.2%. 
Since the concentration in the donor, i.e., the driving force for penetration 
was the same in all cases (2 mg/ml) the results point to much more aptitude 
of the polymers to cross the excised intestinal wall compared to the small-
MW NaFlu. NaFlu is known to cross the intestinal epithelium via the tight 
junctions between enterocytes [195,196], i.e., the paracellular route. This 
cannot be the penetration route of the polymers as well, either as free 
macromolecules or crosslinked NP, considering their extremely large size 
compared with the NaFlu molecules, and yet, their much higher penetration 
rates resulting from data in Fig. 3. Perhaps an active transcellular transport 
mechanism of NP must be called forth to explain such data, which would 
involve NP endocytosis at the apical cell membrane, particle transport 
through the cells, and finally, NP release at the basolateral side [197]. Such a 
type of transport is related to particle size and is optimized when this ranges 
from 50 to 500 nm [198, 21]. In fact, the size of the NP made from FITC-
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QA-rCh60 was 370.5±1.7 nm (polydispersity, 0.582±0.022), and that of the 
NP made from FITC-QA-rCh60-SH was 452.1±12.1 nm (polydispersity, 
0.595±0.000). The values of the mass fractions penetrated appear from Fig.3 
to be close for the two NP types, nevertheless, although slightly, that for the 
thiolated ones seems significantly higher, perhaps due to their thiols making 
them more mucoadhesive. It should also be stressed that, as stated in the 
Introduction, the thiolated NP type was found in a previous study to be 
internalized by EPC [190]. In order to gain useful indications in support of 
the above hypothesis on the penetration mechanism sections of intestinal 
wall were observed under a fluorescence microscope following incubation 
with NP. The microphotographs in Fig. 4 show discrete fluorescent spots all 
across the gut section, representative of integral NP penetrating from 
mucosal to serosal side of the intestine. This allows us to safely state that the 
NP did not disintegrate in their transit across the intestinal barrier. Hence, 
the fluorescence measured in the acceptor medium in the course of the 
penetration studies can be ascribed to dispersed NP, coming from the NP 
dispersion in the donor, potentially apt to be internalized by EPC. 
 
 
2.5.3	CONCLUSIONS			
The main GSE antioxidant components have been identified. GSE-loaded 
NP, freshly prepared from either thiolated or non-thiolated quaternary 
ammonium-rCh conjugate, have shown a comparatively high EE and a size 
apt for internalisation by cells. In fact, following incubation of NP 
dispersions with the mucosa of excised rat intestine in an Ussing chamber, 
the NP have been found to migrate from donor to acceptor compartment, and 
seen on a fluorescence microscope to penetrate across the intestinal wall 
from mucosal to serosal side in an integral state, i.e., preserving their 
supramolecular nature. After lyophilisation the NP dispersion could be 
regenerated from the dry product with water and gentle stirring. The 
particles of the regenerated dispersion have shown some increase in size, but 
this was not so marked as to exceed the reported limit for the particles able 
to cross the intestinal barrier. On the other hand the fraction of GSE 
associated with the regenerated NP decreased considerably with respect to 
the EE of the freshly prepared NP. Still the regenerated NP steadily retained 
a significant level of GSE for a term presumably sufficient for NP 
penetration across the intestinal epithelium into the bloodstream and 
internalisation by EPC along with their load of antioxidant material. The 
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results obtained in the present study have indicated no important differences 
between the properties of NP made from thiolated and non-thiolated rCh 
derivatives that could be ascribed to the different mucoadhesivity of these 
polymers. One such difference perhaps consists in slightly more aptitude of 
the NP derived from the thiolated polymer to be absorbed across the 
intestine. Taking into account the ability of whichever NP type (thiolated or 
not) to carry significant GSE amounts it can be affirmed that the present 
lyophilised nanoparticulate systems show promise of making up sound 
vehicles for oral administration of beneficial doses of GSE. 
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2.5.4	TABLES	AND	FIGURES	
 
Table 1. Spectral (UV and ESI-MS) and chromatographic (HPLC) data of 
compounds (1-9) detected in GSE preparation. 
 
Peak Compounds t0 (min) 
[M-H]- 
(m/z) 
MS/MS Fragments 
(m/z) λmaz 
1 Procyanidin trymer 1,2,3 7.03 865  280 
2 Procyanidin Β1 13.40 577 559,451,425,407 280 
3  Catechin 14.24 289 271,245,205,179 280 
4 Procyanidin trymer 1,2,3 15.22 865  280 
5 Procyanidin Β2 16.5 577  280 
6 Epicatechin  17.12 289  280 
7 Procyanidin trimer 4 19.69 865  280 
8 Procyanidin dimer 1,2,3 20.38 729 711,603,577,451,407,289 280 
9 Epicatechin gallate 23.25 441 285 275 
 
Table 2. Characteristics of freshly prepared GSE-loaded NP dispersions. 
 
NP based on PB molarity of NP dispersion 
Mean particle 
size±SD (n=6), nm 
Polydispersity 
index±SD (n=6) 
EE±SD 
(n=3), % 
QA-rCh60 
0.007 347.3±28.3 0.920±0.047 82.0±2.1 
0.013 312.7±17.6 0.770±0.047 81.2±1.7 
0.026 330.8±3.9 0.578±0.007 83.2±3.2 
0.13 332.5±30.8 0.678±0.066 64.1±1.9 
QA-rCh60-SH 
0.007 288.7±7.5 0.715±0.020 81.1±0.4 
0.013 307.7±15.3 0.682±0.052 81.5±1.4 
0.026 296.7±6.7 0.519±0.018 80.7±2.8 
0.13 347.3±28.3 0.599±0.031 70.0±2.1 
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 Table 3. Characteristics of GSE-loaded isosmotic NP dispersions 
regenerated after lyophilisation 
  
NP based on 
Regeneration 
water volume, 
mL 
Polymer 
concentration, 
mg/mL 
Mean particle 
size±SD (n=6), nm 
Polydispersity 
index±SD (n=6) 
QA-rCh60 
0.3 33.3 934±19.6 0.852.0±0.058 
0.5 20 799.2±70.8 0.476±0.280 
1 10 407.1±0.6 0.508±0.076 
5 2 592.7±79.9 0.634±0.045 
QA-rCh60-
SH 
0.3 33.3 447.4±55.1 0.693±0.072 
0.5 20 617.9±80.5 0.470±0.152 
1 10 432.4±9.97 0.420±0.075 
5 2 478.1±32.6 0.543±0.050 
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Figure 1. LC-PD-ESI-MS chromatographic profile of GSE preparation at 
(A) PDA Total scan, (B) 280 nm, (C) MS Base Peak. 
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Figure 2.  GSE release from lyophilized/regenerated nanoparticles: Time 
variation of GSE fraction in nanoparticles matrix (NP) or  dispersion 
medium (DM), for NP based on QA-rCh60 (A) or QA-rCh60-SH (B). 
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Figure 3.  Fluorescent mass fraction penetrated across the excised rat 
intestinal wall in one hour incubation. Donor phase: A, Na Flu solution; B, 
GSE-loaded NP dispersion based on FITC-QA-rCh60; C, GSE-loaded NP 
dispersion based on FITC-QA-rCh60-SH. 
Initial fluorescent mass concentration in donor phase 2 mg/mL. 
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Figure 4.  Microphotographs of slices of rat intestinal wall observed under a 
light (A-C) or fluorescence (D-H) microscope following 1 h incubation in an 
Ussing chamber with NaFlu solution (A,D); FITC-QA-rCh 60-based NP 
(B,E,G) or FITC-QA-rCh 60-based NP (C,F,H). Hematoxylin-eosin stained 
sections (A,B) show intact intestinal wall. While no fluorescence is evident 
in control sample (D), noticeable fluorescent spots are present in FITC-NP 
treated samples (E-H). Fluorescence is localized all across the section, from 
mucosal (M) to serosal (S) layer and the level of vessels (arrows) (G,H). G 
and H show greater magnification of boxes in E and F, respectively. Scale 
bar 50 µm. 
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2.6	THERMOSENSITIVE	HYDROGELS	BASED	ON	CHITOSAN	AND	
ITS	DERIVATIVES	CONTAINING	MEDICATED	NANOPARTICLES	FOR	
THE	TRANSCORNEAL	ADMINISTRATION	OF	5-FLUOROURACIL		
Ocular drug delivery is one of the most challenging task for pharmaceutical 
scientists. The unique structure of the eye restricts the entry of drug 
molecules at required site of action. More than 90% of the marketed 
ophthalmic formulations are in the form of eye drops but are washed from 
the eye by various mechanisms (lacrimation, tear dilution and tear turnover) 
resulting in low ocular bioavailability of drugs. Moreover, human cornea 
comprising epithelium, substantia propria and endothelium restricts the entry 
of drug molecules [214]. As a result of these factors less than 5% of 
administered drug enters the eye.  
Colloidal carriers have been widely exploited in the field of drug delivery 
science because they provide a more selective targeting with sustained 
release of molecules at the desired site and could be used in the treatment of 
diseases affecting the anterior as well as the posterior segment of the eye. An 
ideal therapy requires selective targeting of active agent for various diseases 
like choroidal neovascularization (CNV), diabetic retinopathy and solid 
tumors in the eye. Retina does not posses lymphatic system and 
angiogenesis in this part of eye has similar features as the solid tumor with 
enhanced permeability and retention (EPR) effects [215, 216.] Delivery of a 
drug via nanotechnology fulfills mainly three objectives: 1) enhancing drug 
permeation; 2) controlling drug release and 3) drug targeting [216]. Another 
interesting approach is the use of hydrogel systems. Hydrogels are polymers 
endowed with the ability to swell in water or aqueous solvents and undergo a 
sol-gel transition. In particular, preformed hydrogels do not allow accurate 
and reproducible administration of drugs and, after administration, they 
often produce blurred vision, crusting of eyelids and lachrymation. Thus, the 
most promising approach is the use of in situ-forming hydrogel that can be 
instilled as eye drops and undergo an immediate gelation when in contact 
with the eye [217]. In-situ-forming hydrogels are liquid upon instillation and 
undergo phase transition in the ocular cul-de-sac to form viscoelastic gel and 
provide a response to environmental changes [218]. 
In the light of the above information, in the present study, we felt it 
intriguing to combine the characteristics of a thermosensitive hydrogel with 
those of nanoparticles, to promote transcorneal penetration of 5-fluorouracil 
(5-FU). Among the various mucoadhesive polymers described in the 
literature, the cationic polymer chitosan (Ch) has been considered the 
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polymer of choice to prepare nanoparticles and hydrogels because of its 
positive charge and ability to intimately interact with cornea and 
conjunctiva, which are negatively charged. In hydrogel formulation, in some 
cases small fractions of chitosan were substituted with quaternary 
ammonium-chitosan conjugates (QA-Ch) or thiolated derivatives thereof 
(QA-Ch-SH) [115] because of their improved mucoadhesivity and ability to 
promote transcorneal penetration [2]. Nanoparticles medicated with 5-FU 
were lyophilized and dispersed in the sol phase. This system undergoes an 
immediate gelation when in contact with the physiological temperature of 
the eye and was administered in vivo in the rabbit eye.  5-FU was chosen as 
the model drug as it is the drug of first choice for the treatment of ocular 
cancer. A 1% 5-FU solution is currently being used by ophthalmologist, 
which is a high concentration for ophthalmic application. Bioavailability in 
the anterior segment of the eye is less than 5% of the applied dose because 
of drainage, lacrimation and poor retention at the absorption surface [219]. 
The ability of hydrogels containing nanoparticles to enhance transcorneal 
penetration of 5-FU has been tested in this study. 
 
2.6.1. MATHERIAL AND METHODS 	
2.6.1.1 Materials 
5-Fluorouracil (5-FU), chitosan low Molecular weight (Ch), β-
glycerophosphate disodium salt (β-GP) and trehalose dehydrate were from 
Sigma-Aldrich. Fluorescein Isothiocyanate (FITC) was from Fluka.  The 
quaternary ammonium-chitosan conjugates, QA-Ch and thiolated 
derivatives, QA-Ch-SH, were synthesized from Ch according to Zambito et 
al. [115]. Nylon membrane 6.6 and cellulose membrane were soaked at least 
24h in water. All aqueous solutions/dispersions were prepared with 
deionized water. All other chemicals and solvents were of reagent grade. 
 
2.6.1.2 FITC-labelling of Ch 
A previously described procedure was followed [192, 193, 108.] 
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2.6.1.3 Preparation of medicated nanoparticles 
FITC-labelled or unlabelled Ch based nanoparticles, medicated with 5-FU, 
self-assembled upon gradual addition of 50 µL portions of a 950 µL volume 
of rHA 1mg/mL and 5.21 mg/mL of 5-FU in demineralized water, to 5 mL 
of 1 mg/mL FITC-labelled or unlabelled Ch in demineralized water. The 
final 5-FU concentration in the nanoparticle dispersion was 1.25 mg/mL. 
Following preparation, the nanoparticles were checked for size (Nano Z690 
Malvern). Their drug entrapment efficiency (EE) was evaluated by 
subjecting the dispersion to centrifugation (28 800 rpm, 1h at 4°C) and 
analyzing the supernatant for the drug by HPLC. EE was expressed as 
follows: 
EE= (Mt−Ms) ⁄ Mt 
 
where Mt is the total drug used for the preparation and Ms is the mass found 
in the supernatant. 
To obtain stable systems, the drug loaded nanoparticle dispersions were 
lyophilized following addition of 250 mf of trehalose dehydrate as 
cryoprotectant (VirTis advantage, thermal treatment step: −35 °C for 180 
min; drying cycle steps: −30 °C for 360 min; −10 °C for 360 min; +10 °C 
for 240 min; +25 °C for 180 min). The dispersions could be regenerated 
from the respective lyophilized products by adding 5 mL of water under 
gentle stirring. 
 
2.6.1.4 Quantitative analysis of 5-FU 
The quantitative analysis of 5-FU was carried out by HPLC. The apparatus 
(Perkin-Elmer, Milano, Italy) consisted of a series 200 pump, 20 µL 
Rheodyne injector, UV detector and Turbochrom Navigator HPLC software 
(PerkinElmer, Inc., Waltham, MA) for data integration. A Spheri-5 RP 18 
5µm 250×4.6 mm column was used. The mobile phase (flow rate 0.6 
mL/min) was KH2PO4 0.05M-Triethylamine 0.1% and the UV detenction 
was set at 266 nm. Standard curves were constructed by analyzing six 
standard drug solutions in the respective eluents. All standard curves 
produced on different days were linear (r2>0.998) in the concentration range 
5-0.3 µg/mL (limit of quantification (LOQ) 0.2 µg/mL, limit of detection 
(LOD) 0.07 µg/mL ). The retention time was 7.5 min. The concentration of 
each unknown sample analyzed was determined using a standard curve 
produced on the same day. 
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2.6.1.5. Dynamic dialysis studies 
These studies were carried out following already described procedures 
[126]. Briefly, the same porous cellulose membrane (cut-off 12.5 kDa), 
diffusion cell and apparatus were used at the thermostat temperature of 
37°C. At t=0, 0.5 mL of medicated nanoparticles, regenerated after 
lyophilization, were introduced in the donor compartment of the cell. Sink 
conditions were maintained in the receiving phase (100 mL of demineralized 
water). Drug transport across membrane was assed by analyzing the 
receiving phase at intervals for the drug by HPLC.  At the end of each run, 
the particle size in the donor phase was checked. For comparison, kinetic 
data were also obtained with the same membrane and procedure for the plain 
drug solution and this solution containing 0.25 mg/mL of Ch dissolved in 
water. 
 
2.6.1.6 Interrupted dialysis studies 
In the interrupted dialysis experiments, the dialysis was stopped after an 
established time for the start and the drug fraction contained in nanoparticle 
matrices, nanoparticle dispersion medium and acceptor medium was 
determined. This procedure was repeated, running the dialysis for different 
times, to construct the plots of the drug fraction in each phase versus time. 
To determine the drug fraction in the dispersion medium and calculate that 
in nanoparticles matrix, ultracentrifugation of donor phase followed by 
analysis of supernatant was carried out. 
 
2.6.1.7 Preparation of thermosensitive hydrogels medicated with 
5-FU 
Thermosensitive hydrogels were prepared by dispersing 500 mg of Ch in 18 
mL of a 0.08M HCl solution. The resulting solution was kept under 
magnetic stirring at 4°C and 476 µL of a β-glycerophosphate (β-GP) 
solution (0.8 g/mL) were added dropwise. The resulting solution was heated 
to 35 °C after which a sol/gel transition was observed. The same procedure 
was followed to prepare thermosensitive hydrogels from QA-Ch50 or QA-
Ch60 or QA-Ch50-SH or QA-Ch60-SH mixtures. The volume of β-GP 
necessary for the gelation of each preparation at 35 °C is reported in Table 1. 
Thermosensitive hydrogels containing 5-FU or 5-FU medicated Ch 
nanoparticles were prepared according by the same procedure. 
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2.6.1.8 Confocal microscope and images analysis 
To evaluate the possibility of re-dispersion of lyophilized NP into hydrogel 
systems, labelled-NP, prepared as described in the Section 2.6.1.3, were 
dispersed in the Ch-QA-Ch50 (4:1) solution and observed under a confocal 
microscope (CLSM; TCS SP5, Leica, Heidelberg, Germany).  Images were 
captured at 21 °C and 35 °C.  
 
 
2.6.1.9 Determination of drug-polymers interactions 
	
Case	of	fluid	solution  
The dynamic dialysis technique described in Section 2.6.1.5 was used to 
determine drug-polymers interactions in fluid solution. Briefly, the same 
porous cellulose membrane (cut-off 12.5 kDa), diffusion cell and apparatus 
were used at the thermostat temperature of 4 °C. At t=0, 5 mL of Ch/β-GP or 
Ch/derivatives/β-GP solution, prepared as described in the section 2.6.1.7, 
were introduced in the donor compartment of the cell. Sink conditions were 
maintained in the receiving phase (100 mL of chloride acid 0.08 M and β-
GP). Drug transport across the membrane was assed by analyzing the 
receiving phase at interval for the drug.  
 
Case	of	semisolid	solution	
Six cells, each containing a 0.2 cm thick layer (2mL) of gel of known drug 
concentration (1.25 mg/mL) separated by a non-porous nylon 6.6 membrane 
(surface area, 10.2 cm2) from 7 mL of drug solution in phosphate buffer pH 
7.4, 0.13M (PB) were simultaneously shaken in a water bath thermostated at 
35 °C. The initial drug concentration in PB was different for the different 
cells and spanned a range to encompass the unknown equilibrium 
concentration with semisolid solution. In each cell, the drug tended to 
equilibrate between phases. After an appropriate time interval (6 h), 
sufficient for a positive or negative concentration change in each solution in 
PB to be detectable, such a change was determined and plotted vs. the 
corresponding initial concentration. As expected [227], a straight line with 
negative slope was obtained in all cases (r2≥0.993; n=6), the abscissa 
intersection of which gave the equilibrium concentration with the semisolid 
solution.  
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2.6.1.10 Release studies of 5-FU from hydrogels  
The 5-FU release from hydrogels was carried out using the following 
procedure. The gel (0.5 mL), containing or not medicated nanoparticles, was 
introduced in a Teflon cell. A porous cellulose membrane (cut-off 12.5 kDa) 
was used to separate the gel from the receiving phase (30 mL of phosphate 
buffer pH 7.4 0.13M, PB) and the system was shaken at 35°C. Drug release 
was determined by analyzing the receiving phase at intervals. 
 
2.6.1.11 In vivo studies 
For in vivo tests, four types of medicated ophthalmic drops were prepared 
having the following composition: 
• 5-FU in PB (1.25 mg/mL, control); 
• a solution containing Ch and 1.25 mg/mL 5-FU; 
• a solution containing Ch-QACh50 (4:1) and 1.25 mg/mL 5-FU; 
• a dispersion of Ch nanoparticles medicated with 1.25 mg/mL 5-FU in 
Ch-QA-Ch50 (4:1). 
 
Male, New Zealand albino rabbits weighing 3.0-3.5 kg, maintained under 
standard stabulation conditions, were used. They were treated as prescribed 
in the ‘Guide for the Care and Use of laboratory Animals’ (NIH Publication 
no. 92-93, revised 1985). All experiments were carried out under veterinary 
supervision and the protocols were approved by the Ethical Scientific 
Committee of the University of Pisa and the Ministry of University and 
Research. To evaluate irritation in the rabbit eyes caused by the ophthalmic 
drops studied, a modified Draize test was conducted [220]. For measuring 5-
FU intraocular penetration, one drop (50 µL) of each solution was instilled 
in the lower conjunctival sac of the rabbit eye. After pre-established times 
rabbits were anesthetized by instilling one drop of Novesina®, then ~60 µL 
of aqueous humor were aspirated from the anterior chamber. For analysis, 
each sample was mixed with acetonitrile (1:2), then it was centrifuged and 
the supernatant was subjected to evaporation for the acetonitrile heating the 
mixture at 50°C under air steam. The aqueous product was then lyophilized. 
The corresponding lyophilized product was re-dispersed in a volume of 
mobile phase corresponding to the initial aqueous withdrawn and analyzed 
by HPLC [37]. 
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2.6.1.12 In vivo data treatment 
The AUC for the aqueous humor was calculated by the linear trapezoidal 
rule between 0 and 8h. The statistical methods described by Schoenwald et 
al. [221] were used in comparing AUC values.  
 
 
2.6.2 RESULTS AND DISCUSSION 
 
2.6.2.1 Characteristics of medicated nanoparticles immediately 
after preparation and after regeneration of lyophilized products 
In Table 2 are reported the mean particle size, the polydispersity index (PI) 
and the EE of freshly prepared nanoparticles together with that of 
nanoparticles regenerated from the lyophilized products. In all cases the PI 
values point to sufficiently homogeneous size distribution according to PI 
values reported in several literature articles [222, 223, 224]. The EE values 
are substantially similar. These results altogether indicate that, nanoparticles 
could be effectively protected from the mechanical stress caused by the ice 
crystallization by adding the cryoprotectant trehalose. 
 
2.6.2.2 Drug release from nanoparticles 
Drug release from nanoparticles was studied by a procedure based on the 
interrupted dialysis followed by ultracentrifugation of donor phase [225], as 
described in the Methods section. The results of the kinetic analysis of 
phases, carried out in this work are plotted in Figure 1. The release of the 
drug from the nanoparticles was complete after 180 min. 
 
2.6.2.3 Drug-binding studies 
Dynamic dialysis data were used to assess reversible drug interactions with 
the chitosan in solution or the surface of the nanoparticles in dispersion. The 
dynamic dialysis data obtained in this work were plotted according to the 
following equation [126, 131]: 
 
ln [(Cd ⁄ Cd0) × 100] = 4.605 − Km Ff t     (1) 
 
where Cd is the drug concentration in donor phase at time t, Cd0 is the drug 
concentration in donor phase at time t=0, Ff is the non-interacting to total 
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drug ratio in donor phase and Km is the dialysis rate constant. The dialysis 
data for plain 5-FU, 5-FU loaded nanoparticles and 5-FU in the presence of 
Ch in solution, are reported in Figure 2 as ln (Cd ⁄ Cd0) × 100 versus t. All 
plots of Figure 2 are significantly linear, as shown by the respective r2 
values, listed in Table 3. Such a linearity indicates that in all cases Equation 
(1) is obeyed and Ff is actually constant with varying Cd and t at least over 
the time of dialysis. Also the slopes of log-linear plots are listed in Table 3. 
For the plain drug, Ff = 1, hence, according to Equation (1), the slope of the 
relative log-linear plot is equal to the dialysis rate constant, Km. From here, 
the drug fraction reversibly interacting with the surface of nanoparticles was 
significantly higher than that of Ch in solution. 
 
2.6.2.4 Characteristics of thermosensitive hydrogels medicated 
with 5-FU 
The volume of β-GP needed to produce an immediate gelation at 35 °C, for 
each formulation is reported in Table 1. β-GP produced gelation increasing 
the pH into the physiological range of 7.0-7.4. The presence of 5-FU or 5-
FU loaded-nanoparticles did not influence this gelation. 
2.6.2.5 Confocal microscope and images analysis 
The microphotographs of FITC-labelled medicated NP are reported in 
Figure 4: the Figure 4 a) is referred to the dispersion at 21 °C while the 
Figure 4 b) to the hydrogel at 35°C. As can be seen, NP are re-dispersed in 
the in situ-forming hydrogel solution and the gelation does not involve 
modifications to NP dispersion. The particles dimensional analysis is 
reported in Figure 5. It appears that the mean diameter is 360 nm, not 
significantly different from that of freshly prepared NP, listed in Table 2. 
The use of confocal microscope was necessary because it was not possible to 
determine the NP mean particles size by Dynamic Light Scattering since the 
polymers in solution interfered with the measurements.    
 
2.6.2.6 Determination of drug-polymers interactions  
Case	of	fluid	solution	
Dynamic dialysis data were used to assess reversible drug interactions with 
the polymers used to prepare the thermosensitive hydrogels. The same 
considerations regarding the Section 2.6.2.2 can be done. The dialysis data 
for plain 5-FU (control), and different polymers used to prepare the 
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hydrogels, are reported as ln (Cd ⁄ Cd0) × 100 versus t in Figure 3 (a) and (b). 
All plots of Figure 3 (a) and (b) are significantly linear, as shown by the 
respective r2 values, listed in Table 4. From the data, it appears that the 5-FU 
interaction, in the presence of QA-Ch60 and QA-Ch60-SH, was lower when 
the presence of Ch derivatives was high. Whereas, the 5-FU interaction, in 
the presence of QA-Ch50 and QA-Ch50-SH, was in all cases not significant. 
Case	of	semisolid	solution	
The positive or negative concentration change in each solution in PB was 
plotted versus correspondent initial concentration. All plots were 
significantly linear, as shown by the respective r2 values listed in Table 5, 
with a negative slope. From the data, it appears that 5-FU equilibrium 
concentration, in the presence of QA-Ch and QA-Ch-SH was significantly 
lower probably due to a strong interaction drug-gel. This strong interaction 
is perhaps due to stiffening of the polymer network that could correlate to 
the presence of fixed positively charges of chitosan derivatives. This 
hypothesis is confirmed by the higher interaction drug-gel registered with 
the conjugate QA-Ch50 (20%). Indeed, in this polymer the number of 
quaternary ammonium ions is higher than with the other derivatives. 
 
2.6.2.7 Drug release from hydrogels 
Drug release from hydrogels, studied as described in the Section 2.6.1.9 and 
reported in Table 6, has shown that the release of 5-FU from plain hydrogels 
was slower when the concentration of the Ch derivatives QA-Ch60, QA-
Ch60SH, QA-Ch50 and QA-Ch50SH in the mixture was higher (20%). 
Furthermore, it can be observed in Table 6 that the cumulative percentage of 
5-FU released from the NP containing hydrogels QA-Ch50 (20%) was 
significantly lower than that released from the other formulations. In the 
case of the NP containing hydrogels, the 5-FU percentage released at t=5h 
was lower than that released at t=2h from the plain hydrogels. This 
difference is particularly evident in the case of the gels containing 20% of 
QA-Ch50. These data altogether encouraged us to choose this formulation 
for the in vivo tests. 
 
2.6.2.8 In vivo tests  
The ophthalmic drops when instilled in rabbit eyes were biocompatible and 
caused no apparent irritation signs, such as conjunctival/corneal edema 
and/or hyperaemia. 
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The relevant concentration-time profiles are shown in Figure 6, while the 
pharmacokinetic data are listed in Table 7. Data obtained following 
instillation of an equal drug dose by 5-FU eyedrops are also reported as 
reference. 
The in vivo tests shown in Figure 6 demonstrate the ability of the hydrogels 
to increase the bioavailability with respect to the control. The 
thermosensitive hydrogels produced a Cmax and a AUC significantly higher 
than that relative to the reference. However the AUC value relative to the 
hydrogel of plain Ch is significantly lower than that relative to the hydrogel 
containing Ch derivatives. This is probably due to the ability of the gels 
containing 20% of QA-Ch50 to control the release of 5-FU. The AUC values 
shown in Table 7, relative to the QA-Ch50 hydrogels containing or not NP, 
were not significantly different. However, the NP containing hydrogels 
shows a concentration plateau in the range 0.5-7h. This pattern points to a 
zero-order transcorneal absorption kinetics, which can be ascribed to 
controlled drug release from hydrogels accompanied by NP internalization 
by the corneal cells. 
 
2.6.3	CONCLUSIONS	
 
Thermosensitive hydrogels were successfully prepared from solutions of Ch 
and its derivatives. The sol/gel transition occurred in the interval 30-35°C. 
The residence time in the precorneal area and the bioavailability of 5-FU in 
the aqueous were increased with respect to the reference. The NP containing 
hydrogels mediated to a zero-order 5-FU absorption, leading to a time-
constant anticancer concentration in the aqueous for 7 hours from 
instillation. 
  
	 111	
 
2.6.4	TABLES	AND	FIGURES	
 
Table 1. Characteristics of the thermosensitive hydrogels 
 
Code Ch conc (mg/mL) Ch derivative Conc (mg/mL, %) β-GP (µL) 
Ch  27.8 - 476 
QA-Ch60  25 2.8, 10 400 
QA-Ch60  23.6 4.2, 15 450 
QA-Ch60  22.2 5.6, 20 450 
QA-Ch60-SH  25 2.8, 10 400 
QA-Ch60-SH 23.6 4.2, 15 425 
QA-Ch60-SH 22.2 5.6, 20 450 
QA-Ch50  25 2.8, 10 400 
QA-Ch50  23.6 4.2, 15 450 
QA-Ch50  22.2 5.6, 20 450 
QA-Ch50-SH  25 2.8, 10 400 
QA-Ch50-SH  23.6 4.2, 15 450 
QA-Ch50-SH  22.2 5.6, 20 476 
 
Table 2. NP characteristics 
 	
 
  
 			 	
Freshly prepared NP 
dimensions (nm; 
PI±SD) 
Regenerated NP 
dimensions, (nm; 
PI±SD) 
EE±SD 
285.6 ± 36.1; 
0.320 ± 0.05 
341.5 ± 15.2; 
0.315 ± 0.45 36.6 ± 3.1 
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Figure 1. Kinetic analysis of dialysis phase for 5-FU loaded nanoparticles 
regenerated after lyophilization.	Key:	,	nanoparticle matrix;	n, nanoparticle 
dispersion medium;	p,	acceptor medium.   	
 
 										
Figure 2.  Plots of dynamic dialysis data according to Equation (1). In donor 
phase, 5-FU (1.25 mg/mL) alone (control) or in the presence of Ch (0.25 
mg/mL) or NP-Ch (regenerated after lyphilization). 
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Table 3. Results of analysis of dynamic dialysis data for 5-FU plotted in 
Figure 2 according to equation (1). 
 
Binding Agent 
Modulus of 
straight line slope 
± SD, h-1, 
r2 Interactiona (%) 
Control 0.8410 ± 0.02* 0.999 − 
Ch 0.9142 ± 0.052 0.994 8.7 
NP-Ch 0.5435 ± 0.019 0.996 35.4 
 
*Dialysis rate constant 
aReversibly bound drug fraction. 
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Figure 3.  Plots of dynamic dialysis data according to Equation (1). In donor 
phase, 5-FU (1.25 mg/mL) alone (control) or in the presence of Ch and Ch 
derivatives QA-Ch60 and QA-Ch60-SH (a) or Ch derivatives QA-Ch50 and 
QA-Ch50-SH (b). 
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Table 4. Results of analysis of dynamic dialysis data for 5-FU plotted in 
Figure 3 (a) and (b) according to equation (1).	
 
Binding Agent Modulus of straight line slope (× 103) ± SD, min-1 r
2 Interactiona (%) 
Control 5.06 ± 0.75* 0.998 - 
Ch  3.47 ± 0.23 0.993 31.4 
Ch + QA-Ch60 (10%) 3.62 ± 0.13 0.995 28.5 
Ch + QA-Ch60 (15%) 4.40 ± 0.12 0.997 13.0 
Ch + QA-Ch60 (20%) 4.77 ± 0.07 0.999 5.7 
Ch + QA-Ch60-SH (10%) 4.40 ± 0. 18 0.996 13.0 
Ch + QA-Ch60-SH (15%) 4.92 ± 0.10 0.998 2.8 
Ch + QA-Ch60-SH (20%) 5.14 ± 0.09 0.998 ns c 
Ch + QA-Ch50 (10%) 4.81 ± 0.18 0.999 4.9 
Ch + QA-Ch50 (15%)  4.94 ± 0.01 0.997 2.4 
Ch + QA-Ch50 (20%) 4.88 ± 0.04 0.999 3.6 
Ch + QA-Ch50-SH (10%) 4.72 ± 0.19 0.998 6.7 
Ch + QA-Ch50-SH (15%)  4.83 ± 0.14 0.997 4.5 
Ch + QA-Ch50-SH (20%)  4.87 ± 0.23 0.993 3.8 
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Table 5. Results of differential dialysis. 5-FU initial concentration (1.25 
mg/mL). 
 
Binding agent Equilibrium concentration in PB x102, mg/ml r
2 
Ch 16.1 0.997 
QA-Ch60 (10%) 6.1 0.997 
QA-Ch60 (15%) 6.5 0.999 
QA-Ch60 (20%) 6.7 0.991 
QA-Ch60-SH (10%) 7.9 0.998 
QA-Ch60-SH (15%) 6.7 0.999 
QA-Ch60-SH (20%) 7.1 0.999 
QA-Ch50 (10%) 8.5 0.997 
QA-Ch50 (15%) 5.5 0.993 
QA-Ch50 (20%) 4.6 0.999 
QA-Ch50-SH (10%) 15.7 0.995 
QA-Ch50-SH (15%) 12.8 0.993 
QA-Ch50-SH (20%) 12.9 0.999 
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Table 6. Cumulative % of 5-FU released from plain or NP containing 
hydrogels 
 
Systems Release from plain hydrogels at t=2h±SD (%) 
Release from NP containing 
hydrogels at t=5h±SD (%) 
Ch 83.0 ± 3.6 82.8 ± 4.7 
QA-Ch60 (10%) 81.7 ± 3.8 79.6 ± 3.9 
QA-Ch60 (15%) 85.3 ± 3.1 78.7 ± 3.8 
QA-Ch60 (20%) 66.0 ± 2.8 78.9 ± 0.6 
QA-Ch60-SH (10%) 89.9 ± 2.2 82.2 ± 4.2 
QA-Ch60-SH (15%) 79.2 ± 2.5 86.0 ± 3.9 
QA-Ch60-SH (20%) 68.0 ± 2.6 76.2 ± 2.9 
QA-Ch50 (10%) 72.2 ± 3.9 84.1 ± 7.6 
QA-Ch50 (15%) 77.7 ± 3.1 69.5 ± 1.5 
QA-Ch50 (20%) 65.1 ± 2.1 59.5 ± 0.9 
QA-Ch50-SH (10%) 88.0 ± 2.0 86.5 ± 1.8 
QA-Ch50-SH (15%) 89.0 ± 2.3 87.9 ± 2.3 
QA-Ch50-SH (20%) 63.4 ± 3.6 78.4 ± 3.8 
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Figure 4. Microphotographs of FITC-labelled NP observed under a confocal 
microscope (a,b, scale 10 µm; c, scale 1µm). 	 	a)	 b)	
c)	
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Figure 5. Dimensional analysis of FITC-labelled NP. 
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Figure 6. Pharmacokinetics in the aqueous following instillation of 
ophthalmic drops. Means±SD of at least six values obtained with different 
animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7. Pharmacokinetic data in the aqueous following instillation of one 
ophthalmic drop (50 µL). 
	 	
Formulation Cmax, µg/ml Tmax, h AUC0-8h, µg h/ml AUCrel 
Control 0.62 0.25 0.643 - 
Ch 0.54 1 1.415 2.2 
QA-Ch50 (20%) 0.50 2 2.318 3.6 
NP-QA-Ch50 (20%)   2.235 3.5 
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